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ABSTRACT 
Klebsiella pneumoniae is an opportunistic bacterial pathogen that is emerging as a 
major global threat as an infectious agent. This organism, along with many other 
pathogens, possesses a broad suite of antibiotic resistances that can make treatment 
exceedingly difficult. As such, the impetus for creating novel antibiotics is at an all-time 
high despite the fact that pharmaceutical investment into drug development is at an all-
time low. S-adenosylmethionine (SAM) is a universally utilized metabolite involved in a 
wide array of biosynthetic processes, and whose products are catabolized by a different 
set of enzymes in mammals than used by many bacteria, protozoa, and plants. This 
divergence provides two specific targets for enzymatic inhibition in K. pneumoniae: 5’-
Methylthioadenosine/S-adenosylhomocysteine Nucleosidase (MTN) and 5-
Methylthioribose Kinase (MTRK). In order to examine the potential effects of drugs 
targeting these enzymes, recombinant proteins from K. pneumoniae were isolated and 
purified, and a profile of their respective kinetic activities were determined. The MTRK 
enzyme was identified as using an ordered sequential mechanism, and shows preferential 
binding towards substrate analogs with hydrophobic 5-alkylthio substitutions. In addition, 
binding affinities of transition state-analogs and novel non-nucleoside small molecule 
inhibitors of MTN were quantified. Finally, the effects of MTN inhibitors on K. 
pneumoniae whole-cell growth, and gene expression were assessed. A number of the 
inhibitors demonstrated strong affinities for the MTN enzyme and induced alterations in 
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cellular growth, autoinducer response, and the expression of genes associated with 
virulence. 
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CHAPTER ONE: INTRODUCTION 
Infectious Diseases 
Microbial infections have been responsible for some of the most devastating 
events in human history. The bubonic plague, smallpox, cholera, tuberculosis and 
innumerable other infectious agents will forever be remembered because of the immense 
impact they have had on human lives. It is no wonder, then, that the advent of antibiotic 
drugs in the mid-20th century stands among the greatest of human achievements. 
However, the efficacy of drug treatments have universally waned from the moment of 
their introduction. Resistance mechanisms towards new antibiotics have inevitably 
sprung forth after their use in the market, often in the span of just a few short years 
(Figure 1.1). 
 
Figure 1.1. Timeline of antibiotic use and appearance of drug resistance. Adapted 
from Clatworthy, et al., 2007. 
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The short efficacious lifespan of new antimicrobials has disincentivized 
pharmaceutical companies from investing resources in further antibiotic research and 
development. This has led to a critical decline in the number of new treatments available, 
while the prevalence of antibiotic-resistant organisms steadily rises (Spellberg, et al., 
2004). Current trends suggest we are moving towards the emergence of a so-called “post-
antibiotic” era, in which we will once again lack the means to medically treat infections 
(WHO, 2015). The implications of this are drastic considering approximately 720,000 
nosocomial infections and 75,000 resultant deaths occur every year in the United States 
alone (Magill, et al., 2014). Globally, 90 million people contracted malaria and 2.6 
million contracted pneumonia in 2014 (WHO, 2014). In fact, mortality from infectious 
and parasitic diseases accounts for 19.1% of global deaths, even in our current pre-“post-
antibiotic” world (WHO, 2004).  
As such, a new class of antimicrobial drugs would be more valuable now than at 
any time since prior to the discovery of penicillin. However, in view of the rate of 
evolutionary acquisition of resistance, it is critical that efforts be made to limit the ability 
for pathogens to quickly develop a means of subverting a drug’s mode of action. Modern 
thinking asserts that molecules that interfere with microbial pathogenicity rather than 
survival will reduce the selective pressure that leads to antibiotic resistance, and allow 
natural immunity to fight off an infection. Therefore, drugs that are designed with these 
precepts should be capable of preventing or delaying the emergence of drug resistance. 
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Klebsiella pneumoniae 
Classification and Threat 
Klebsiella pneumoniae is a Gram-negative rod shaped bacteria in the 
Enterobactericeae family. While part of the normal flora of the human body, various 
strains possess high pathogenic capacity, especially while acting as a nosocomial agent 
and towards people with pre-existing conditions resulting in compromised immune 
systems (e.g. diabetes, alcoholism, HIV, etc.). Its modes of pathogenicity allow it to 
clinically manifest as urinary tract infections, pneumonia, septicemia and soft tissue 
infections. Klebsiella pneumoniae accounts for 3-7% of hospital-associated bacterial 
infections (Podschun, et al., 1998), placing it among the eight most prevalent infectious 
pathogens. However, the greatest concern towards K. pneumoniae is due to the drug 
resistance profile of many clinical isolates. Pathogenic strains often carry plasmid-born 
resistances, and K. pneumoniae was among the first organisms found to possess genes for 
aminoglycoside resistance and extended-spectrum β-lactamase (ESBL) activity, which 
confers resistance to cephalosporins and aztreonam (Arnold, et al., 2011).  
In the early 1990’s, a novel β-lactamase was found in Klebsiella, termed 
“Klebsiella pneumoniae carbapenemase” (KPC). KPC confers resistance to virtually all 
β-lactam drugs, including penicillins, cephalosporins, monobactams, and carbapenems 
(Arnold, et al., 2011). This was a critical development as carbapenems are a class of drug 
with regulated medical use as a “last resort” treatment for Gram-negative bacterial 
infections in order to preserve their efficacy and longevity. The KPC gene proved to be 
highly mobile and spread rapidly among other Gram-negative species, creating a class of 
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organisms known as “carbapenem-resistant Enterobactericeae” (CRE). The KPC gene is 
now the most commonly found carbapenemase gene worldwide (Nordmann, et al., 2009).  
In 2009, a new carbapenemase gene with a novel mode of action was isolated 
from K. pneumoniae (Yong, et al., 2009). Named the “New Delhi metallo-β-lactamase”, 
this gene is also rapidly spreading across the globe and among other Gram-negative 
bacteria such as E. coli, Enterobacter cloacae, and Salmonella enterica. A survey of New 
Delhi carbapenemase-bearing clinical isolates in the U.S. showed that all of them also 
possessed resistance to additional antibiotics including aminoglycosides and 
fluoroquinolones, and also possessed one or more alternate β–lactamases (Rasheed, et al., 
2013). Due to difficulty of treatment, CRE organisms are significantly more virulent, 
with mortality rates for septic patients at 71.9% vs. 21.9% for non-CRE infections (Borer, 
et al., 2009). The rate of occurrence is also increasing, with the proportion of CRE 
infections accelerating from 0.6% to 5.6% during 2004-2008 (Gupta, et al., 2011). K. 
pneumoniae currently poses a major threat to the medical community and is poised to 
become an even greater danger in the near future.  
Pathogenic strains of K. pneumoniae possesses a suite of traits that help to enable 
their capacity for infection and morbidity, which include: mucoviscosity, cellular 
adhesion, biofilms, and siderophores. 
Mucoviscosity 
High mucoviscosity, often referred to as hypermucoviscosity, is a common 
characteristic of many infectious strains of K. pneumoniae. Manifesting as an 
extraordinarily thick accumulation of extracellular capsular polysaccharide (CPS) 
surrounding the cells. Positive strains can be readily identified by a “stringiness” of the 
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colonies (Figure 1.2). The capsule serves as a physical buffer that helps exaggerate 
bacterial defense mechanisms. 
 
Figure 1.2. Hypermucoviscous Klebsiella pneumoniae. This positive stretch test of a 
hypermucoviscous strain shows the characteristic stretch of a mucoid colony. (Shon, et 
al., 2013). 
The hypermucoviscosity trait strengthens defense against host immune responses 
and contributes significantly to host mortality during infection. K. pneumoniae strains of 
the K1 and K2 serotypes most highly associated with hypermucoviscosity express an 
estimated 15-17 genes implicated in upregulation of CPS synthesis (Wu, et al., 2009; 
Arakawa, et al., 1995). Of these, the magA gene (K1 strains), confers complete resistance 
to bactericidal human serum and a greater than 105-fold decrease to the lethal dose in 
mice (Fang, et al., 2004). High capsule production in both serotypes are reported to 
confer resistance to opsonin-dependent phagocytosis by human neutrophils (Domenico, 
et al., 1994). Non-capsule forming K. pneumoniae mutants showed drastically reduced 
virulence in mouse pulmonary infections (Chhibber, et al., 2003). These findings 
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highlight the importance of capsule production as a virulence factor in K. pneumoniae 
infections. 
Cellular Adhesion 
Many pathogenic strains of K. pneumoniae possess the ability to bind to the 
surface biomolecules of mammalian cells. This is achieved largely through the action of 
extracellular structures referred to as pili or fimbriae. These long, thin columnar 
structures protrude from the cell membrane through the capsular layer and facilitate 
binding to extracellular matrix proteins and cell surface markers (Proft, et al., 2009). 
Pathogenic K. pneumoniae genomes encode two distinct adhesive fimbriae, designated as 
type 1 and type 3. Type 1 fimbriae are characterized by their capacity to agglutinate 
guinea pig erythrocytes (Figure 1.3). They are also responsible for adhesion to human 
bladder and tracheal cells (Fader, et al., 1979; Fader, et al., 1988). In contrast, type 3  
 
Figure 1.3. Structure of a type 1 fimbriae. The main body is comprised of a helix of 
repeating subunits and is capped by a single adhesive subunit. Fimbriae can range in 
length from 1 to 2 µm. (Adapted from Bodelon, et al., 2013.) 
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fimbriae are characterized by their ability to only agglutinate tannin-treated erythrocytes, 
and enable adhesion to respiratory tissues (Hornick, et al., 1992). These fimbriae also 
confer bacterial adherence towards plastic surfaces (Jagnow, et al., 2003) and the 
ubiquitously expressed extracellular matrix proteins (collagen, fibrinogen, and 
fibronectin) found in epithelial tissues (Hennequin, et al., 2007). 
Multiple plasmid-borne adhesive factors also exist in K. pneumoniae. The 
adhesive factor CF29K was acquired from other enteropathogens, and mediates binding 
to gastrointestinal tissues (Martino, et al., 1995). Interestingly, high capsule production 
antagonizes tissue adherence. This is proposed to occur by blocking adhesive factor 
accessibility due to excess capsule (Schembri, et al., 2005). Tissue specific 
downregulation of capsule production may act as an early adaptive response that 
facilitates bacterial adherence at the site of infection (Vartivarian, et al., 1993). 
Subsequent upregulation of capsule production may later improve virulence by protecting 
the pathogen from host immune responses. 
Biofilms 
Recent studies indicate that the many decades of research examining in vitro 
bacterial cultures may have focused on a mostly irrelevant planktonic growth phase. 
Under natural growth conditions, bacteria more often form complex microbial 
communities called biofilms. These colonies are formed from extracellular secretions of 
carbohydrates, proteins and DNA that form a dense connective network that enmeshes 
the cells together (Figure 1.4). Bacterial behavior within these structures is highly 
modified, displaying functions that are not observed in free planktonic growth.  Cells 
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growing within biofilms are known to undergo an alteration in their expression of surface 
markers, nutrient metabolism, and in their virulence profiles (Schembri, et al., 2003).  
 
Figure 1.4. Extracellular components of biofilms. Biofilm deposition is facilitated 
by bacterial adhesins and flagella. The polymeric matrix is composed mostly of structural 
polymers like colonic acid, cellulose, polyglucosamine (PGA), and extracellular DNA 
(eDNA) (Kostakioti, et al., 2013). 
Biofilm formation is initiated by cellular adhesion to either living tissue or abiotic 
surfaces, especially in response to adhesion by type 1 fimbriae (Pratt et al., 1998). 
Plastics are particularly prone to biofilm formation, contributing heavily to the incidence 
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of catheter-related urinary tract infections (Trautner & Darouiche, 2004). Following 
initial bacterial adhesion, various extracellular biofilm constituents are secreted. The 
composition of these secreted molecules are dictated heavily by environmental factors 
(Harmsen, et al., 2010). Biofilm formation is found to be highly dependent on expression 
of the type-3 fimbriae subunit MrkA in K. pneumoniae (Schroll, et al., 2010). Biofilms 
permit the accumulation of Autoinducer (AI) signaling molecules and the second 
messenger, 3,5-cyclic diguanylic acid (c-di-GMP), which induce alterations in gene 
expression to promote biofilm maturation and expansion (Kostakioti, et al., 2013).  
Compared to free-living organisms, microbes within biofilms possess traits that 
enable environmental survival and are therefore more likely to cause clinical disease. The 
inherent hydrophilicity of polysaccharides produces a “slime” that helps prevent cell 
desiccation, and the physical nature of biofilms results in resistance to removal from 
surfaces by shear forces. Cells cloistered within biofilms are also physically protected 
from human immune responses (Jesaitis, et al., 2003). Poor diffusional properties within 
these biomaterials, combined with metabolic changes that are not fully characterized 
result in an upwards of 500-fold increase in antibiotic resistances (Costerton, et al., 
1995).  
Even more pernicious is the existence of internal “persister” cells. These deeply 
embedded cells experience an environment of nutrient and oxygen deprivation that 
induces a state of metabolic stasis. The cessation of nearly all molecular activity grants 
inherent insensitivity towards many antibiotics. However, persister cell activity can be 
resumed following the death of nearby non-persister cells in response to antibiotic 
treatment (Lewis, 2005). As a result, biofilm-associated infections often require surgical 
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removal of affected tissues to prevent chronic recurrence. The co-localization and 
concentration of cell populations in biofilms have also been found to expedite lateral 
gene transfer, facilitating the spread of plasmid-borne drug resistances and virulence 
factors (Flemming, & Wingender, 2010).  
Siderophores 
Siderophores comprise a class of secreted small molecules that act as metal ion 
chelators and are used primarily to scavenge iron from the environment and import it into 
the cell. Iron is a vital component of enzymes involved in many cellular processes, 
including respiration and DNA synthesis. The vast majority of iron in humans is 
sequestered within hemoglobin, ferritin, and transferrin, leaving a free Fe3+ ion 
concentration of approximately 10-24 M (Vasil, & Ochsner, 1999). However, optimal 
growth conditions for microorganisms require roughly 1 µM of iron, requiring a means of 
extracting host iron to enable efficient proliferation by pathogens (Miethke, et al., 2008). 
There are dozens of physically distinct siderophores produced by Gram-negative bacteria, 
with no discernable conservation of type utilized, even by closely related species. A 
survey of 475 K. pneumoniae strains showed 98.8% produced siderophores (Podschun, et 
al., 1992) with aerobactin being the most relevant form utilized during infection (Russo, 
et al., 2015). Previous research has shown that genetic knock-outs of siderophore genes in 
K. pneumoniae produce avirulent strains (Hsieh, et al., 2008), thus identifying 
siderophores as a requisite component of pathogenicity. The rmpA gene, one of the most 
widely shared enhancers of CPS among K. pneumoniae strains, has been reported to be 
downregulated at high iron concentrations (Cheng, et al., 2010).  Potentially, siderophore-
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mediated loss of capsule synthesis may improve the ability of the organism to establish 
new sites of colonization during a septic infection. 
 
Figure 1.5. Structural diversity of bacterial siderophores. Iron chelating groups are 
highlighted and color coded by common structure. (Adapted from Miethke & Marahiel, 
2007.) 
5’-Methylthioadenosine/S-adenosylhomocysteine Nucleosidase 
Function and Prevalence 
S-adenosylmethionine (SAM or AdoMet) is one of the most widely used 
molecules in biochemical pathways and is the second most utilized enzymatic substrate 
after ATP (Fontecave, et al., 2004). Four of the most critical SAM functions are  
 
 
Figure 1.6. Depiction of substrate-bound E. coli MTN. Ribbon diagram of the MTN 
enzyme co-crystallized as a native homodimer with two bound non-hydrolyzable MTA 
analog molecules in the active sites (Lee, at al., 2001; PDB: 1NC1). 
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transmethylation reactions, bacterial autoinducer production, polyamine synthesis, and 
radical SAM reactions. The enzyme 5’-methylthioadenosine/S-adenosylhomocysteine 
nucleosidase (known as MTN, mtnN, or MTAN) is responsible for the irreversible 
depurination of several metabolic products of SAM-dependent reactions by addition of a 
water molecule. MTN is a functional homodimer with each unit mutually forming part of 
two symmetric binding sites (Figure 1.6). Bacterial MTN catalyzes the breakdown of 
three known substrates: 5’-methylthioadenosine (MTA), S-adenosylhomocysteine (SAH), 
and 5’-deoxyadenosine (5’dADO). The products of MTN reactions are recycled via 
purine and methionine salvage pathways (Figure 1.7). In mammals, the analogous 
enzyme activities are performed by two different enzymes: 5’-methylthioadenosine 
phosphorylase (MTAP) and S-adenosylhomocysteine hydrolase (SAHH). MTAP is a 
homotrimer with similar but not identical binding site properties to MTN, and catalyzes 
the reversible phosphorylytic depurination of MTA. SAHH is evolutionarily distinct and 
does not deadenylate the substrate SAH. Instead it resembles an enzymatic class of NAD-
dependent hydrogenases and cleaves the 5’ carbon-sulfur bond of SAH to yield adenosine 
and homocysteine using an NADH cofactor (Turner, et al., 2000). 
The buildup of MTA and SAH are both toxic to cells (Christa, et al., 1988) and 
strong product inhibitors of the pathways that form them (Parveen & Cornell, 2011). As a 
result of the expansive number of enzymes involved in radical SAM reactions there is 
still an incomplete profile of the consequences of 5’dADO buildup. However, it also has 
been characterized as a product inhibitor for some of its dependent enzymes, such as 
biotin and lipoyl synthases (Choi-Rhee & Cronan, 2005). 
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Figure 1.7. Central role of MTN on SAM-dependent metabolic pathways. 
Bacterial MTN facilitates the deadenylation of three distinct products of S-
adenosylmethionine (SAM) dependent reactions. 
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The accumulation of these three nucleosides as a result of MTN inhibition is 
therefore expected to act as a powerful means of debilitating a multitude of biochemical 
pathways. Despite the central role of MTN in these diverse metabolic functions, it is not 
strictly required for cellular survival. MTN gene knock-out strains (MTN KOs) of 
Staphylococcus aureus and Neisseria meningitides grew normally in nutrient replete 
media, but showed reduced virulence (Bao, et al., 2013; Heurlier, et al., 2009). MTN KO 
strains of E. coli (RK4353, O157:H7) showed reduced growth rates, altered metabolism, 
and decreased toxin production (Knippel, 2013). This supports a role for MTN in the 
promotion of organismal growth and the expression of virulence factors instead of cell 
survival. As a result, targeting MTN with chemotherapeutics should enable the host 
immune system to more effectively cope with infection, placing the drugs themselves 
under less selective pressure for the development of antibiotic resistance (Clatworthy, et 
al., 2007). The MTN enzyme is relatively well conserved among bacteria, being found in 
51 of 138 bacterial species examined (Parveen & Cornell, 2011) and is also utilized  by 
various parasites, such as Entamoeba histolytica (Larson, et al., 2010) and Giardia 
lamblia (Riscoe, et al., 1988). MTN is also found in most plant species, where it plays a 
role in synthesis of the hormone ethylene (Kushad, et al., 1985). The broad organismal 
utilization of MTN could allow a potent MTN inhibitor to act as a broad-spectrum 
antimicrobial against a diverse array of organisms. 
Previous efforts at designing inhibitors for MTN have largely consisted of 
attempts to create molecules that act as either early or late-stage transition state analogs 
(TSAs). The underlying principle is that enzymes function by stabilizing an energetically 
unfavorable intermediate transition between the reactants and products. Thus, the affinity 
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of the enzyme towards molecules resembling that intermediate state are theorized to 
exceed that of the natural substrates by a factor equal to the rate of catalytic acceleration 
(Wolfenden, et al., 2001). The mechanism of MTN during catalysis is initiated by the 
protonation of N7 of the adenyl group, followed by a donation of electron density from 
the ribose ring oxygen and SN1-type dissociation of the purine from the ribose. 
Afterwards, a localized water molecule attaches to the resultant highly reactive 
ribooxacarbenium ion (Figure 1.8). Efforts have thus centered around modifying electron 
density and bond length properties on the 1’ carbon, examining the influence of 5’ 
alkylthio substitutions, and utilizing a non-hydrolyzable glycosidic bond to prevent the 
drugs from enzymatic degradation.  
Efforts to create TSA inhibitors of bacterial MTN have been remarkably 
successful. Dissociation constants for some late-stage TSA inhibitors have been as low as 
47 femtomolar against E. coli MTN, which represents a 91 million-fold greater binding 
affinity than for the substrate SAH (Singh, et al., 2005). These inhibitors represent some 
of the tightest binding non-covalent inhibitors for any known enzyme. Unfortunately, 
their observed effects on cellular behavior have typically been less dramatic. V. cholerae 
growth in media supplemented with a TSA inhibitor at a million-fold concentration 
greater than the Ki failed to affect growth (Schramm, et al., 2008). 
However, TSA drugs applied even at picomolar concentrations were found to 
disrupt autoinducer-2 and biofilm formation in both V. cholerae and E. coli (Gutierrez, et 
al., 2009). More recently, ten different MTN inhibitors were discovered to significantly 
reduce growth in Helicobacter pylori and are being examined as species-specific  
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Figure 1.8. Rationale for MTN transition-state analog design. A) Representation of 
MTN catalysis of 5’-methylthioadenosine to 5-methylthioribose and adenine. B) 
Examples of both early and late-stage transition state inhibitors. Both possess non-
hydrolyzable bonds on the equivalent of the 1’ carbon, with bond elongation in the late-
stage analog. Early onset (unmarked) inhibition values were derived from initial enzyme 
velocities. Delayed-onset (*) inhibition values are derived from the kinetic rates 
following thermodynamic equilibrium of the drug-enzyme complex (data from Singh, et 
al., 2005). 
antibiotics (Wang, et al., 2015). To date, no data regarding MTN inhibitor effects on K. 
pneumoniae growth have been published. 
In order to be useful as chemotherapeutic agents, MTN inhibitors should 
demonstrate little to no effect on human cells. MTAP is the mammalian enzyme with 
greatest homology to MTN, and thus with the greatest concern for unintended inhibition. 
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While MTAP also acts on the substrate MTA, it uses a different nucleophile (phosphate) 
to effect a reversible cleavage of the glycosidic bond to generate adenine and MTR-1-
phosphate. Though similar to MTN in function, the differences in active sites are drastic 
enough to allow the design of molecules that preferentially inhibit MTN without 
significantly affecting MTAP (Longshaw, et al., 2010). In particular, the clustering of 
positively charged amino acids near the ribosyl 2’ carbon for MTAP, and its more 
occluded binding site near the 5’ carbon have been proposed as exploitable differences 
for drug design (Lee, et al., 2003). An extensive analysis of TSA inhibitors have shown 
up to a 1300-fold binding discrimination favoring MTN over MTAP (Longshaw, et al., 
2010).  
A broad variety of extremely powerful transition state analog inhibitors of the 
MTN enzyme have been identified. Due to MTN’s diverse role in multiple metabolic 
pathways, enzymatic inhibition of this enzyme is expected to induce changes the 
metabolic processes involved in transmethylations, the production of autoinducers and 
polyamines, radical SAM reactions contributing to vitamin and cofactor synthesis, and 
methionine salvage. 
Activated Methyl Cycle 
Transmethylations are a ubiquitously utilized biological process. Methyl 
recipients include most main classes of biomolecules: phospholipids, proteins, nucleic 
acids, carbohydrates, and some small molecules like catechol and glycine. More than 
twenty distinct SAM-dependent methyltransferases have been identified (Chiang, et al., 
1996). DNA methylation is the most studied function of methyltransferases, where the 
cytosine residues in CpG motifs are methylated to regulate histone association and mark 
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cell cycle progression (Cheng, et al., 2001). Additional methyl recipients include rRNA 
(Vester & Long, 2009), tRNA (Urbonavicius, et al., 2005), proteins that affect enzymatic 
activity and influence signal transduction, and L-rhamnose sugars, which are methylated 
before incorporation into the glycan chains in bacterial cell walls (Steiner, et al., 2008). 
While the complete role of phospholipid methylation is still debated, it is known to 
function as an alternate synthetic method for creating phosphatidylcholine (Chiang, et al., 
1996). A summary of known methyl recipient molecules and the processes that are 
affected are shown in Table 1.1.  
Table 1.1. Effects of molecular methylation, by acceptor type. 
DNA Gene repression, genome imprinting, replication timing, 
development, DNA repair 
Protein Protein function (via charge, orientation, hydrophobicity, etc.), 
signal transduction, chemotaxis, growth phase regulation 
Lipids Phosphatidylcholine synthesis, calcium transport, adenylate 
cyclase activation, signal transduction 
Carbohydrates Glycan formation 
Small molecules Neurotransmitter degradation, amino acid synthesis 
 
SAM is the most common methyl group donor, and the product of these reactions 
is SAH (Figure 1.9). Transmethylation reactions are subject to product inhibition by SAH 
at low micromolar concentrations (Caudill, et al., 2001). 
 
Figure 1.9. Mechanism of general SAM-dependent methyltransferase activity. 
SAM represents the most widely utilized source of methyl donor groups. 
19 
 
Autoinducer Production 
Autoinducers (AIs) are a class of small molecules utilized by single-celled 
organisms as a means of coordinating group behavior in a process known as “quorum 
sensing”. First discovered in V. fischeri and V. harveyi, autoinducer signaling was 
responsible for stimulating bioluminescence in response to high cellular concentration 
(Kaplan & Greenberg, 1985). Later studies discovered quorum sensing was a mechanism 
utilized by a large number of Gram-positive and Gram-negative bacteria. Processes 
influenced by quorum sensing include bioluminescence, spore formation, biofilm 
development, and virulence factor secretion (Rutherford, et al., 2012). Most Gram-
negative bacteria are capable of producing two distinct forms of autoinducers, AI-1 and 
AI-2.  
AI-1 is formed from the methionyl group of SAM that spontaneously cyclizes 
upon addition of a hydrocarbon chain from acyl-carrier protein (ACP). The acyl chain 
length varies between bacteria and is thereby considered to be a form of species-specific 
communication. AI-2 is formed by isomerization of the ribose moiety of S-
ribosylhomocysteine (SRH) to 4,5-dihydroxy-2,3-pentanedione (DPD). In aqueous 
environments, DPD cyclizes and forms a complex with aqueous boric acid (Figure 1.10). 
AI-2 is invariant among species and thought to act as a universal quorum sensing 
molecule. As AI-2 synthesis is dependent on a product of MTN metabolism and AI-1 is 
subject to feedback inhibition by MTA, both signaling pathways are highly dependent on 
nucleosidase activity. 
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Figure 1.10. Synthetic pathways of Autoinducers 1 and 2. A) Production of AI-1 
from SAM and acyl carrier-protein. The reaction is mediated by LasI and creates an acyl 
homo-serine lactone with a hydrocarbon chain length that varies depending upon the 
species. B) Synthesis of AI-2 from S-ribosylhomocysteine, as mediated by LuxS. This 
reaction creates 4,5-dihydroxy-2,3-pentadione (DPD). DPD spontaneously cyclizes to the 
precursor molecule 1-deoxy-3-dehydro-D-ribulose (pro-AI-2), which exists in 
equilibrium with an active borate diester form (AI-2). 
K. pneumoniae lacks the AHL synthase enzymes required to create AI-1 and 
relies solely on AI-2. AI-2 deficient mutants of the LuxS gene in K. pneumoniae 
displayed structural impairments in early biofilm formation (Balestrino, et al., 2005). K. 
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pneumoniae knock-out strains for AI-2 transport proteins were also shown to have an 
increase in the production of extracellular lipopolysaccharides (Araujo, et al., 2010).  
Polyamine synthesis 
Polyamines are small organic polycations utilized by all forms of life and are 
considered as an element of the minimal metabolome of cells (Lee, et al., 2009). The 
positive charges enable interactions with negatively charged molecules like DNA, 
proteins, and cell wall components. In bacteria, polyamines are known to play a role in 
DNA replication, transcription, translation, cellular growth, siderophore synthesis, 
swarming, and biofilm formation (Lee, et al., 2009). Regulation of apoptosis is also 
known to be under partial control by polyamines (Seiler & Raul, 2005). There are four 
major polyamines synthesized in most organisms: putrescine, spermidine, spermine and 
cadaverine. Among bacteria, spermine and cadaverine are often synthesized only in trace 
amounts. Many bacteria, including K. pneumoniae, are incapable of synthesizing 
spermine. In contrast, putrescine and spermidine are heavily utilized, with intracellular 
concentrations typically in the low millimolar range (Shah & Swiatlo, 2008). The 
biosynthetic pathway for polyamines is initiated by the formation of putrescine from 
either L-ornithine or L-arginine. Both spermidine and spermine are synthesized by the 
addition of a propylamine group from decarboxylated SAM to putrescine and spermidine, 
respectively (Figure 1.11). These events are catalyzed by spermidine and spermine 
synthases and form MTA as a byproduct. Cadaverine is synthesized through an 
independent mechanism, in which L-lysine is converted to cadaverine directly by lysine 
decarboxylase. MTA acts as a product inhibitor of both spermidine and spermine 
synthases (Pajula & Raina, 1979; Evans, et al., 2004).  
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Figure 1.11. Spermidine synthesis. Formation of spermidine from putrescine and 
decarboxylated S-adenosylmethionine (dcSAM) via the spermidine synthase enzyme. 
The addition of a second aminopropyl group from dcSAM to spermidine by spermine 
synthase produces the polyamine spermine. Spermine is not usually synthesized de novo 
in bacteria, but can be formed in the presence of exogenous spermidine (Shaw & Swiatlo, 
2008). 
Radical SAM syntheses 
Radical SAM enzymes constitute a recently discovered superfamily whose 
function is dependent on a conserved CxxxCxxC amino acid domain, with a non-
conserved fourth cysteine contributing to a catalytic [4Fe-4S] cluster (Challand, et al., 
2009). Radical SAM functions encompass more than 40 distinct synthetic processes with 
a conserved mechanism by which the iron-sulfur cluster facilitates the removal of 
methionine from SAM to produce a 5’-deoxyadenosine radical (Figure 1.12). The radical 
is quickly transferred to either another substrate or onto the SAM radical enzyme by the 
abstraction of a hydrogen atom. Some functions of SAM radical enzymes include: DNA 
 
Figure 1.12. The general mechanism of radical formation and transfer by SAM 
radical enzymes. The 5’-deoxyadenosine radical species transfers the radical electron by 
the abstraction of a hydride group from the target small molecule or enzyme. 
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repair, anaerobic DNA metabolism, lipoyl production, and the synthesis of the cofactors 
pyrroloquinoline quinone, biotin, and thiamine (Frey, et al., 2008). Thiamine (vitamin B1) 
is an essential cofactor in the central carbon metabolism of both glucose and pentose 
sugars (Figure 1.13). Thiamine deficiency is known to cause significant defects in 
cellular proliferation (Gigliobianco, et al., 2010). The radical SAM enzymes biotin 
synthase, lipoyl synthase, thiamine synthase, and tyrosine lyase are all subject to product 
inhibition by a combination of 5’dADO and methionine (Challand, et al., 2009).  
 
Figure 1.13. The role of thiamine as a cofactor in central carbon metabolism. 
Thiamine is crucial for the function of enzymes involved in glycolysis, the citric acid 
cycle, and the pentose phosphate pathway. (Adapted from Harrigan, et al., 2008.) 
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Methionine salvage pathway enzymes – 5-methylthioribose kinase (MTRK) 
5-Methylthioribose Kinase 
Methionine recycling is intertwined with all three MTN substrates. MTRK is the 
enzyme responsible for initiating methionine salvage from 5-methylthioribose (MTR), 
the product of MTA depurination by MTN. MTRK facilitates the phosphate transfer from 
ATP to carbon-1 of MTR (Figure 1.14). Unlike MTN, the MTRK enzyme is utilized by a 
much more restricted group of bacteria (Klebsiella, Bacillus, Rhizobium, etc.). MTRK is 
also broadly present in plants but is absent in mammals, suggesting it could be a good 
target for species-specific antibiotic or herbicide development.  
The methionine salvage pathway (Figure 1.14) begins with MTA produced from 
SAM-dependent polyamine or AI-1 synthesis. MTN depurinates MTA to produce 
adenine and MTR. MTRK then catalyzes the phosphotransfer reaction from ATP to MTR 
to produce 5-methylthioribose-1-phosphate (MTR-1P). In K. pneumoniae, the remainder 
of the pathway is as follows: MTR-1P undergoes isomerization to methylthioribulose-1-
phosphate, and is subsequently dehydrogenated to 2,3-diketo-methylthiopentane-1-
phosphate. This is then dephosphorylated to 1,2-dihydroxy-3-keto-5-methylthiopentene, 
which is then oxidatively decarboxylated to 2-keto-4-methylthiobutyrate (KMTB). 
KMTB is then selectively transaminated to reform methionine.  
This process is adhered to by many organisms, with slight variations among 
species. Methionine is also a product of radical SAM reactions and can be recycled from 
homocysteine, a product of SAH breakdown. The recycling of methionine is an important 
function, as the molecule is energetically costly to synthesize de novo. Many  
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Figure 1.14. Methionine salvage cycle in Klebsiella pneumoniae. The activity of the 
alternative mammalian MTAP pathway is denoted by a dashed line. 
organisms lack synthetic enzymes to create methionine, and rely upon the salvage 
pathways to conserve this amino acid (Albers, 2009). As MTRK is not utilized by 
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mammals, it has undergone investigation as a potential target of antibiotic development. 
A large number of MTR analogs with substitutions of the 5-alkylthio moiety have proved 
successful in inhibiting MTRK activity. Substituted 5-phenylthioribose analogs in 
particular have demonstrated strong effects on K. pneumoniae growth, the most potent of 
which displayed an IC50 value of 2.5 picomolar (Winter, et al., 1993). The analogs 5-
trifluoromethylthioribose (TFMTR) and 5-ethylthioribose (ETR) have been demonstrated 
to act as catalyzable substrates and continue through downstream metabolism to produce 
the toxic molecules of carbonothioic difluoride (thiophosgene gas) and ethionine, 
respectively (Gianotti, et al., 1990; Tower, et al., 1991; Winter, et al., 1993). The broad 
acceptance of MTR analogs as either functional inhibitors or accepted substrates shows 
an high degree of substrate promiscuity which may provide opportunities for exploitation 
in future drug designs.  
Summary 
The bacterial organism Klebsiella pneumoniae acts as an important nosocomial 
pathogen and is poised to become an even greater threat in the near future. K. 
pneumoniae possesses two enzymes, 5’-methylthioadenosine nucleosidase (MTN) and 5-
methylthioribose kinase (MTRK), which are not found in humans. These enzymes 
contribute to many important metabolic functions, which include: transmethylations, 
autoinducer synthesis, polyamine production, radical SAM reactions, and the salvage of 
methionine. As a result, MTN and MTRK have been identified as targets for the 
development of novel antimicrobial therapeutics. The research presented here consists 
largely of efforts following the purification of these two enzymes from genes cloned and 
expressed from the K. pneumoniae genome. Chapter 2 (pg. 27) presents a manuscript 
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derived from the characterization of the kinetic properties, substrate affinity, and kinetic 
mechanism of the MTRK enzyme. Chapter 3 (pg. 46) reports a manuscript based on 
investigations into MTN regarding kinetics towards the three unique substrates, and the 
determination of inhibition constants for several transition state analog and novel non-
nucleoside small molecule inhibitors. Chapter 4 (pg. 61) contains research towards a third 
publication that investigates the in vitro effects of MTN inhibitors against K. pneumoniae 
regarding growth, biofilm formation, autoinducer-2 secretion, and the transcriptional 
expression of multiple virulence factors. 
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CHAPTER 2: PAPER #1 – CHARACTERIZATION OF Klebsiella pneumoniae 5-
METHYLTHIORIBOSE KINASE 
Abstract 
5-Methylthioribose kinase (MTRK) is an enzyme unique to the methionine 
salvage pathway of plants and some microbes. The MTRK enzyme catalyzes the 
phosphorylation of 5-methylthioribose (MTR), a product of the synthesis of polyamines, 
autoinducer-1, and ethylene, in order to initiate the methionine salvage pathway. The 
absence of MTRK in mammals has established this enzyme as a potential target for the 
development of novel antibiotics. Analysis of genomic data for MTRK reveals a high 
degree of sequence homology between diverse organisms, and suggests the presence of 
both methionine and purine-dependent regulatory elements for MTRK gene expression in 
the nosocomial pathogen Klebsiella pneumoniae. A K. pneumoniae recombinant MTRK 
enzyme was cloned and purified and the Km values for MTR and ATP were found to be 
21 ± 2 and 70 ± 10 µM respectively, with a specific activity of 6.2 ± 0.2 µmol/min per 
mg. Investigation into substrate acceptance of MTR analogs with substitutions at the 5-
carbon position demonstrated a high affinity towards groups with hydrophobic properties. 
Product inhibition studies using MTR-1-phosphate (MTR-1P) suggest an ordered 
sequential reaction mechanism with ATP binding first and MTR-1P being the first 
product released.  
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Introduction 
Methionine salvage is important for the recycling of methionine utilized in S-
adenosylmethionine (SAM) dependent methylation reactions, polyamine synthesis, and 
the radical SAM reactions involved in vitamin biosynthesis [8, 21, 26]. Recovery of 
methionine from MTA is a highly conserved function [26], as the de novo synthesis of 
methionine is considered to be energetically “costly”. Indeed, many organisms lack de 
novo methionine synthetic pathways entirely and instead rely solely on exogenous 
sources and salvage methods. The utilization of the MTRK enzyme is common among 
plants but highly unusual among bacterial species. Of note among these are the genus 
Serratia, Enterobacter, and Klebsiella. These organisms act as common nosocomial 
agents with significant clinical impacts. The absence of MTRK in mammals and the 
majority of bacterial species provides an opportunity for the development of targeted 
antibiotics that would not disturb the human microbiome. 
The MTRK enzyme is a functional homodimer with a structural homology to the 
choline/ethanolamine kinase enzyme family [17]. It is responsible for committing the 
waste product 5-methylthioribose (MTR) to the salvage pathway by phosphorylation at 
the 1-carbon position, at the expense of ATP. The methionine salvage pathway itself 
(Figure 2.1) is initiated following the addition of methionine to ATP, which produces S- 
adenosylmethionine (SAM or AdoMet). SAM is utilized in an array of biochemical 
processes that produce three major products: S-adenosylhomocysteine (SAH), 5’-
deoxyadenosine (5’dADO), and 5’-methylthioadenosine (MTA). The majority of SAM is 
consumed in transmethylation reactions [31], producing SAH, while 5’dADO is the  
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Figure 2.1. Methionine salvage pathway in Klebsiella pneumoniae. Following the 
utilization of methionine in the production of polyamines via S-adenosylmethionine 
(AdoMet), 5-methylthioribose is progressively restructured into methionine by a suite of 
dedicated enzymes (metK; speD, E; mtnN, K, A, B, C, D, E) [35]. 
product of radical-SAM reactions for vitamin biosynthesis. In the third process, SAM is 
decarboxylated and subsequently loses a propylamine group to produce 5’-
methylthioadenosine (MTA) and the polyamines spermidine or spermine. MTA is also a 
by-product of the synthesis of the signaling hormone ethylene in plants [8], and of the 
quorum sensing molecule autoinducer-1 among Gram-negative bacteria [7]. In mammals, 
MTA is directly converted to 5-methylthioribose-1-phosphate (MTR-1P) by the enzyme 
5’-methylthioadenosine phosphorylase, whereas in plants and certain bacteria, this 
process requires the concerted effort of both the 5’-methylthioadenosine/S-
adenosylhomocysteine nucleosidase (MTN) and MTRK enzymes.  
The pathways for the recovery of methionine following the production of MTR-
1P are highly similar among all organisms. Initially, MTR-1P undergoes an isomerization 
to methylthioribulose-1-phosphate (MTRu-1P), and a successive dehydrogenation and 
dephosphorylation to 1,2-dihydroxy-3-keto-5-methylthiopentene (DHK-MTPene). A 
dioxygenase converts this to 2-keto-4-methylthiobutyrate (KMTB), which is then 
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selectively transaminated to reform methionine. Many organisms catalyze these reactions 
using multifunctional enzymes, with K. pneumoniae utilizing a bi-domain 
enolase/phosphatase and plants such as A. thaliana possessing a 
dehydratase/enolase/phosphatase [26]. 
This work presents a kinetic characterization of the K. pneumoniae MTRK 
enzyme as well as an examination of the kinetic mechanism and MTRK substrate analog 
utilization. 
Materials and Methods 
Bacterial strains and culture conditions. K. pneumoniae ATCC strain 43816 
was used for gene amplification. Protein induction and purification were performed in E. 
coli BL21 (Invitrogen) cells. All growth was performed in Luria-Bertani media at 37°C 
with shaking at 225 rpm. 
Chemicals and substrates. 5’-deoxy-5’-methylthioadenosine (MTA), S-
ribosylhomocysteine (SRH), 5-deoxyribose (5-dRIB), phosphoenolpyruvate (PEP), 
dithiothreitol (DTT), and lactate dehydrogenase/ pyruvate kinase were purchased from 
Sigma. Nicotinamide adenine dinucleotide (NADH) was purchased from Acros Organics, 
and magnesium chloride was acquired through J.T. Baker Chemical Co. MTR and MTR 
analogs were provided by Dr. Michael Riscoe (OHSU). MTR-1P was prepared in lab 
through enzymatic reactions. In short, to a 2mL solution of 1mM MTA and 0.3M sodium 
phosphate of pH=7, 7µg recombinant human MTA phosphorylase (previously purified in 
lab) was added and allowed to react at room temperature over 1.5 hours. The solution 
was then centrifuged through a Merck Millipore 3000 NMWL centrifuge filter, and the 
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flow-through collected. Complete conversion of reactant was verified by the loss of 
activity as a substrate for MTN enzyme (previously purified in lab). 
Gene cloning. The MTRK gene sequence was amplified by whole-cell PCR using 
the primer pair MTRKF (5’- GAATTCATGTCGCAATACCATACCTT – 3’) and 
MTRKR (5’ – GCGGCCGCTCAGCTGTACTGGCGTACCC - 3’), and the PCR product 
was digested and ligated into poly-His-encoding pPROEX HTA plasmid (Invitrogen) at 
the EcoR1/Not1 digest sites. The plasmid was transformed into chemically competent E. 
coli One Shot® TOP10 cells and purified using the GeneJET Plasmid Miniprep Kit 
(ThermoFisher). Insert orientation was confirmed by PCR and sequencing (VA DNA 
Sequencing Core Facility) and the plasmid was transformed into E. coli BL21 cells 
(Invitrogen) and subsequently grown under ampicillin selection.  
Protein purification. 500mL LB were inoculated with the plasmid-bearing strain 
and grown to an OD600 of 0.4. Protein expression was induced with 0.5mM IPTG and the 
cells were then grown overnight. Cells were centrifuged at 5000xG for 15 minutes, 
washed once in 50mL PBS, centrifuged again and the pellet was lysed with 3mL BPER® 
reagent over 15 minutes at room temperature with frequent vortexing. Lysate was then 
centrifuged again and the supernatant was added to 3mL cobalt HisPur™ resin and set to 
agitate at 4°C overnight. Column elutions were performed by centrifugation at 700xG for 
2 minutes, and consisted of a flow-through, three washes with 3mL wash buffer (10mM 
imidazole, 50mM NaPO4, 300mM NaCl, pH= 7.4), and three elutions with 1.5mL 
500mM elution buffer (250mM imidazole, 50mM NaPO4, 300mM NaCl, pH= 7.4). 
Protein identity and purity was confirmed by 15% polyacrylamide SDS-PAGE assessed 
by PageRuler Plus Prestained Protein Standard (ThermoFisher), stained with Coomassie 
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Blue. The enzyme concentration was quantified by A280 (ɛ280 = 1.04 mg/mL). The final 
elution from the purification procedure was used for kinetic analyses, due to highest 
apparent purity, and was quantified at 500ng/µL (data not shown) before being diluted to 
100ng/µL at 20% glycerol for long-term storage and use in spectrophotometric assays. 
MTR kinase enzyme assay. Reaction conditions were based on a linked 
spectrophotometric assay wherein ADP production is stoichiometrically linked in a one-
to-one relationship with NADH oxidation [44]. In brief, assays were performed at 25°C 
in 1mL total volume with 1mM PEP, 0.3mM NADH, 2mM MgCl2, 5mM DTT, 0.1M 
sodium phosphate pH 7, and 14U lactate dehydrogenase (LDH)/ 11U pyruvate kinase 
(PK) (purchased combined from Sigma). Reaction scheme is as follows: 
1) ATP + MTR → MTR-1P + ADP                        Scheme 1 
2) ADP + PEP → ATP + pyruvate 
3) Pyruvate + NADH → lactate + NAD+ 
For kinetic activity determinations, the non-varied substrate was used at a 
concentration approximately ten times the derived Km (200 µM for MTR, 1mM for 
ATP). MTR was examined at concentrations between 1 and 200 µM and ATP between 
10 and 200 µM. After addition of LDH/PK enzymes to substrates, the reaction mixture 
was given 5 minutes to reach equilibrium before addition of 1 µg MTRK and enzymatic 
activity was continually monitored at 340 nm on Varian Cary 50 spectrophotometer (ɛ340 
= 6.22 mM-1 cm-1). Data was analyzed using GraphPad Prism 6.0 software and fit to the 
Michaelis-Menten equation, where: 
ݒo ൌ ݒmaxሾܵሿ ሺܭm ൅ ሾܵሿሻ⁄                    Eqn. 1 
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Alternate substrate assays were performed with 1mM ATP and the MTR analog 
used in lieu of MTR at a concentration of 20 µM.  
Homology modeling. The crystal structure of Bacillus subtilis 2PUP (GI: 
37999472) was obtained from Protein Data Bank (PDB: 4L0M). Homology modeling of 
the Klebsiella pneumoniae sequence (GI: 11846464) was carried out using Maestro and 
Prime (ver. 4.2) of Schrodinger Suite 2015-4 [40]. Sequence alignment of 2PUP and K. 
pneumoniae was conducted using the BLAST algorithm in the structure prediction 
wizard in Prime. The three-dimensional K. pneumoniae structure was modeled using the 
Bacillus subtilis MTRK crystal structure (PDB: 2PUP) as the template. Using the energy-
based approach in Prime, Bgp and MtnN homology models were constructed as homo-
dimers with no ligands in the active sites. The homology model was then aligned with the 
Bacillus subtilis structure (PDB: 2PUP) using Schrodinger. The coordinates of ADP and 
PO42- were copied into the active sites of the K. pneumoniae homology model. 
Molecular docking. Grid generation and ligand docking was performed using the 
Glide (ver. 6.9) [41] algorithm in Schrodinger. Grid generation using the default 
parameters was performed on both of the MTRK structures, with the grid centered in the 
active site and a search radius of 17 Å. Molecular docking of MTR was conducted using 
the standard precision (SP) method and default parameters in Glide. Results were 
visualized in Maestro and images were rendered using Pymol (ver. 1.8) [42]. 
Results and Discussion 
Genomic analysis – Examination of the genomic region surrounding MTRK in K. 
pneumoniae reveals some unexpected structural organization, as well as several putative 
regulatory elements (Figure 2.2). The MTRK gene in B. subtilis has been identified as 
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part of a region containing independent regulons that encode the genes for every enzyme 
of the methionine salvage pathway [24]. In contrast, the K. pneumoniae MTRK gene is 
adjacent only to MTR-1P isomerase (Figure 2.2). These genes are separated by a 101 
base pair region and are encoded on complimentary strands. Present in the promoter 
region separating MTR-1P isomerase and MTRK are multiple consensus sequences for 
metR and metJ regulatory domains. These regulatory mechanisms allow differential 
expression dependent on intracellular methionine availability. The palindromic nature of 
these sequences allows them to potentially operate as shared regulators for the two 
enzymes, though the advantage of separating these genes is hard to surmise, as they fulfill 
a shared metabolic role. These met-regulatory domains account for the observed 
moderation of MTRK activity following growth in methionine-rich environments [16], as 
well as the increased MTRK expression noted under sulfur-starved conditions [17]. The 
regulatory method stands in contrast to that used by B. subtilis, which utilizes the S-box 
sequence found in Gram-positive bacteria, an element common to genes involved in 
sulfur metabolism [35]. The sequence upstream of MTRK also contains a purR 
regulatory sequence, establishing a link to purine metabolism. This is most likely due the 
relationship of MTRK with the enzyme preceding it in the salvage pathway, MTN, which 
acts as a purine nucleosidase. 
36 
 
 
Figure 2.2. Upstream sequence for K. pneumoniae MTRK. The MTRK and MTR-
1P genes are adjacent but not members of an operon. Predicted regulatory sequences 
determined from the consensus sequences for: metJ – AGACGTCT, metR – 
TGAANNATNNTTCA and purR – ACGCAAACGTTTTCNT [36][37][38]. 
A multiple sequence alignment between a set of bacterial and plant MTRK genes 
showed high degrees of homology, with K. pneumoniae possessing a 30-40% residue 
identity to each examined sequence (Figure 2.3). Critically, the residues identified as 
CGCGCCGCGCACCCGCAGGGTATGAATATGGTCCACCAGCAGCGC
AACGTTATCCGCCGCCAGCCAGCGTTTTTCCTGCGGCAAGGCCTG
CTGGTCGAGAATAAAAAGCTGATTTTCACTCACCCGCAGGCTGGT
GGTCTGTAATGTCTGCATGTCGTTAAATCCCTGTTGCGTTGTTGT
ATCACATTGTGTCAGGATGGAATCCAGAAGTATAGACGTCTGAAC
GGCTTAATCAGAATTCGAGGATCGAGGCA ATG TCG CAA TAC
M   S   Q   Y
integrase transposaseMTRK
MTR‐1P
isomerase3‐phytase
purR
MTR-1P isomerase
metJmetJ
metR
metR
MTRK
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K pneumoniae      ------------MSQYHTFTAHDAV-------AYAQQFAGIDNPSELVSAQEVGDGNLNL  41 
B subtilis        -------MGVTKTPLYETLNESSAV-------ALAVKL-GLFPSKSTLTCQEIGDGNLNY  45 
S meliloti        ----------MDKQVFEALSAESLPHRLGGNSALREKI-GGD--VSHWTVKEIGDGNLNL  47 
P difficile       ------------MNNYE---HHMLLDVEEVKCYVTSKL-QYFQKDEVLQAEEIGDGNINY  44 
A thaliana        ----------MSFEEFTPLNEKSLVDYIKSTPALSSKI-GADKSDDDLVIKEVGDGNLNF  49 
O sativa1         MAAAAEQQQQQQQQGFRPLDEASLVAYIKATPALAARL-GGS--LDALTIKEVGDGNLNF  57 
O sativa2         ---MAAAAAEQQQQGFRPLDEASLVAYIKATPALAARL-GGR--LDALTIKEVGDGNLNF  54 
                                      ^       ^ 
K pneumoniae      VFKVFDRQGVSRAIVKQALPYVRCVGESWPLTLDRARLEAQTLVAHYQHSPQHTVKIHHF  101 
B subtilis        VFHIYDQEHDRALIIKQAVPYAKVVGESWPLTIDRARIESSALIRQGEHVPHLVPRVFYS  105 
S meliloti        VFIVTGSKG--TAVVKQALPYVRLVGESWPLPLKRSFFEYHALVRQAARAPGMVPEIFFF  105 
P difficile       VFRVWNPDSGKSIIIKQADKFLRSSGRAL--DVYRNKIEAEILKLEGMLAEGFVPKVYAY  102 
A thaliana        VFIVVGSSG--SLVIKQALPYIRCIGESWPMTKERAYFEATTLRKHGNLSPDHVPEVYHF  107 
O sativa1         VYIVLSDAG--SVVIKQALPYIRCVGDSWPMTRERAYFEASALQKHRGLCPDHVPEVYHF  115 
O sativa2         VYIVLSDAG--SLVIKQALPYIRLVGDSWPMSRERAYFEASALQKHRALCPDHVPEVYHF  112 
                                                              
K pneumoniae      DPELAVMVMEDLS-DHRIWRGELIANVYYPQAARQLGDYLAQVLFHTSDFYLHPHEKKAQ  160 
B subtilis        DTEMAVTVMEDLS-HLKIARKGLIEGENYPHLSQHIGEFLGKTLFYSSDYALEPKVKKQL  164 
S meliloti        DETQALIVMEYLT-PHVILRRALIDGRELPNIGCDLGLFAARTLFRGSDLSMATRDKKAD  164 
P difficile       DETMCVLAMEDIS-AYKNMRKELMEGRFFPHFAENIAEFLARTLLPTTDLVLDRAVKKDN  161 
A thaliana        DRTMALIGMRYLEPPHIILRKGLIAGIEYPFLADHMSDYMAKTLFFTSLLYHDTTEHRRA  167 
O sativa1         DRAMSLIGMRYIEPPHIILRKGLIAGVEYPLLAEHMADYMAKTLFFTSLLYNSTTDHKKG  175 
O sativa2         DRAMSLIGMRYIEPPHIILRKGLVAGVEYPLLAEHMADYMAKTLFFTSLLYNSTTDHKKG  172 
                                  ^ 
K pneumoniae      VAQFI-NPAMCEITEDLFFNDPYQIHERNNYPA-ELEADVAA-LRDDAQLKLAVAALKHR  217 
B subtilis        VKQFT-NPELCDITERLVFTDPFFDHDTNDFEE-ELRPFVEK-LWNNDSVKIEAAKLKKS  221 
S meliloti        LALFADNVELCDITENLVFSDPYFEADLNRHTAPQLDPIVME-LRSDRDLKVEAQRLKHL  223 
P difficile       VRLFL-NKELCDITEDLVLTEPYDNYKNRNIVLPENEEFVKEFLYENEQLKADVAQLRDS  220 
A thaliana        VTEFCGNVELCRLTEQVVFSDPYRVSTFNRWTSPYLDDDAKA-VREDSALKLEIAELKSM  226 
O sativa1         VAQYCDNVEMCRLTEQVVFSDPYMLAKYNRCTSPFLDNDAAA-VREDAELKLEIAELKSM  234 
O sativa2         VAQYCDNVEMSRLTEQVVFSDPYRVAKYNRCTSPFLDNDAAA-VREDAELKLEIAELKSM  231 
                           **+                * *^ 
K pneumoniae      FFAHAEALLHGDIHSGSIFVAEGSLKAIDAEFGYFGPIGFDIGTAIGNLLLNYCGLPGQL  277 
B subtilis        FLTSAETLIHGDLHTGSIFASEHETKVIDPEFAFYGPIGFDVGQFIANLFLNALSRD---  278 
S meliloti        FSAKAETLCHGDLHTGSVMVTDAETRVIDPEFAFYGPISFDVGMLLANFWMSYFSQSGQE  283 
P difficile       FMNHAQALVHGDLHSGSIFINEQGIKIIDPEFAFYGPMGYDIGNVIGNLFFAWARIQFI-  279 
A thaliana        FCERAQALIHGDLHTGSVMVTQDSTQVIDPEFSFYGPMGFDIGAYLGNLILAFFAQDGHA  286 
O sativa1         FIERAQALLHGDLHTGSIMVTPDSTQVIDPEFAFYGPMGYDIGAFLGNLILAYFSQDGHA  294 
O sativa2         FIERAQAFLHGDLHTSSIMVTPDSTQVIDPEFAFYGPMGYDIGAFLGNLILAYFSQDGHA  291 
                          
K pneumoniae      GIRD-AAAAREQRLNDIHQLWTTFAERFQALAAEKTRDAALAY--------------PGY  322 
B subtilis        ------GADREPLYEHVNQVWETFEETFSEAWQKDSLDVYANI--------------DGY  318 
S meliloti        STTGARDGMRAYLLETIETIWETFRSEFAQLWRTERMG--ILYQARVFEDRNDPLGAEQA  341 
P difficile       --EPRYTEFLTWCSHTVADTIDLTMEKLSKVYEQCVE-------CPLY-------RTKEF  323 
A thaliana        TQENDRKEYKQWILRTIEQTWNLFNKRFIALWDQNKDGPGEAYLADIYNNTEVL---KFV  343 
O sativa1         DQANDRKAYKKWILKTIEDSWNLFHKKFVELWNKHKDGNGEAYLPPIYNSSELL---CLA  351 
O sativa2         DQANDRKAYKKWILKTIEDSWNFFHKKFVELWNKHKDGNGEAYLPPIYNSSELL---SLV  348 
                                       **  ^^ 
K pneumoniae      ASAFLKKVWADAVGFCGSELIRRSVGLSHVADIDTIQDDAMRHECLRHAITLGRALIVLA  382 
B subtilis        LTDTLSHIFEEAIGFAGCELIRRTIGLAHVADLDTIVPFDKRIGRKRLALETGTAFIEKR  378 
S meliloti        LNIVIDDIWREMLGFAGIEIHRRILGLAHNADFETIADPDRRAACESKALKLGRHLAVNR  401 
P difficile       KQHYLRDVMSDSLGYAGTEIIRRVVGDSKVMEVTSIKETDKRVAFERALLKMGIWLIRNR  383 
A thaliana        QENYMRNLLHDSLGFGAAKMIRRIVGVAHVEDFESIEEDKRRAICERSALEFAKMLLKER  403 
O sativa1         QKKYMTSLFHDSLGFGSAKMIRRIVGIAHVEDFESIEDASKRASCERRALNCAKAILKGR  411 
O sativa2         QKKYMTSLFHDSLGFGSAKMIRRIVGIAHVEDFESIEDASKRASCERRALNCAKAILKGR  408 
                       
K pneumoniae      ERIDSVDELLARVRQYS-----                                        399 
B subtilis        SEFKTITDVIELFKLLVKE---                                        397 
S meliloti        HRIHSLRDIRATAERLQKETLA                                        423 
P difficile       KVIHEGKEVSEQFNMICS----                                        401 
A thaliana        RKFKSIGEVVSAIQQQS-----                                        420 
O sativa1         RQFESIGQVIVHVQSFDRD---                                        430 
O sativa2         RQFESIEQVIVHVQSFDRD---                                        427 
Figure 2.3. Bacterial and plant MTRK sequence alignment. Represented are 
diverse sequences from K. pneumoniae, B. subtilis, R. meliloti, C. difficile, A. thaliana 
and both O. sativa isotypes. Residues involved in MTR substrate specificity, 
ATP/Mg2+ coordination, and with catalysis are marked above with ^, *, and +, 
respectively. Alignment was performed with ClustalOmega software [33]. 
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comprising the binding pocket and those that participate in substrate/cofactor binding and 
orientation are highly homologous [20]. This suggests a strong evolutionary conservation 
of enzyme in form and function between highly disparate organisms. 
Protein purification – Addition of the N-terminal poly-His selection marker 
resulted in a calculated molecular weight of 48.3 kD, matching the observed weight and 
holding consistent with that previously reported for the native enzyme [2]. The 
recombinant protein was identified by size and the apparent purity was confirmed as 
>95% by SDS-PAGE (Figure 2.4).  
 
Figure 2.4. SDS-PAGE of purified recombinant MTRK. Lane 1: Protein molecular 
weight standard. Lane 2: 2µg recombinant MTRK. The calculated molecular weight for 
purified rMTRK was 48.3 kD. 
Substrate kinetics assays – Results of both MTR and ATP substrate-specific data 
were indicative of typical Michaelis-Menten kinetics (Figure 2.5). The enzymatic rate fell 
within expected parameters, showing a specific activity of 6.2 µmol/min/mg. The 
apparent Km values for both substrates were determined at near-saturating conditions for 
the non-varied substrates. The Km values were demonstrated to be at physiologically 
relevant concentrations of 21 and 70 µM for MTR and ATP, respectively. MTR as a 
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substrate demonstrated a higher catalytic efficiency than ATP by a factor of 3.3 (Table 
2.1).  
 
Figure 2.5. Substrate velocity plots of MTRK. The substrate kinetics for MTR (left) 
and ATP (right) were determined using a coupled spectrophotometric assay. The data 
was fit to the Michaelis-Menten equation using GraphPad Prism 6.0 software. 
The Km for MTR was in close accord with that previously reported from enzyme 
purified from K. pneumoniae cellular extracts at 12.2 µM [2]. Km values from 
Enterobacter aerogenes for MTR and ATP were also placed at 8.1 and 74 µM [15]. A Km 
for ATP had additionally been assigned for the OsMTK1 enzyme from Oryza sativa at 
184 µM [19]. The O. sativa enzyme was also reported to display a significantly slower 
activity than for K. pneumoniae as well as evidence of cooperative binding, which was 
not observed for the K. pneumoniae MTRK. Despite the high degree of homology 
between bacterial and plant MTRK sequences, large discrepancies in activity and binding 
may be possible, though this may simply be an apparent difference as only one of the two 
O. sativa MTRK enzymes was kinetically profiled. 
Alternate Substrate kinetics – Assays were performed under conditions identical 
to prior MTR substrate kinetics assays, with MTR analogs used in lieu of MTR at 20µM  
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Table 2.1. Summary of MTRK kinetic constants 
 Specific Activity kcat Km kcat/Km 
MTR 6.2 ± 0.2 µmol/min/mg 300 ± 8 min-1 21 ± 2 µM 14.2 µM-1min-1
ATP … … 70 ± 10 µM 4.3 µM-1min-1
Km values represent the “apparent” Km measured at conditions with the non-varied substrate held at 
near-saturating concentration 
concentration and standardized to the activity of MTR. Activity was observed for many 
of the substrates examined, and that of n-propylthioribose exceeded that of MTR by a 
significant margin (Table 2.2). The previously identified substrate of 5-
trifluoromethylthioribose showed approximately two-thirds the activity of the native 
substrate, while the singly-halogenated 5-fluoromethylthioribose showed one-fifth 
activity. Analogs with bulkier 5-carbon substitutions showed drastically limited activities. 
β-hydroxy-5-butylthioribose had one-twentieth the native catalytic rate and para-nitro-5-
phenylthioribose showed no catalysis. As MTR is one of three structurally similar 
products of the MTN enzyme, we examined both alternate products of MTN metabolism, 
S-ribosylhomocysteine and 5-deoxyribose. Neither substrate produced any observable 
catalytic activity.  
Table 2.2. Summary of the relative specific activities of MTR analogs. 
Substrate % Activity Specific Activity (µmol/min/mg) 
5-methylthioribose (MTR) 100 6.2 
n-propylthioribose 168 10.4 
5-trifluoromethylthioribose  66 4.1 
5-fluoromethylthioribose 20 1.2 
β-hydroxy-5-butylthioribose 5 0.3 
p-nitro-5-phenylthioribose 0 0 
S-ribosylhomocysteine  0 0 
5-deoxyribose  0 0 
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The capacity of n-propylthioribose as a substrate is not entirely unexpected, as 5-
ethylthioribose (not tested) has been shown to be an inhibitor of microbial growth owing 
to its conversion by MTRK towards the toxic molecule ethionine [27]. The rationale for 
its increased activity is difficult to ascertain, as the conserved Trp74, Leu345, and Leu180 
residues in the B. subtilis crystal structure were proposed to gate the 5-carbon end of the 
ribose molecule in order to restrict the hydrocarbon chain length [20].  
5-trifluoromethylthioribose is a previously identified substrate that is ultimately 
catalyzed to toxic carbonothioic difluoride [10], and exhibited two-thirds the activity of 
MTR whereas the singly halogenated 5-fluoromethylthioribose showed less activity 
despite it more closely resembling the native 5-methylthio group in size. This is most 
likely on account of the hydrophobic nature of saturated fluorocarbons (e.g. Teflon) 
discriminating binding in favor of the trifluoro-substituted analog. Examination of β-
hydroxy-5-butylthioribose displayed an extremely limited degree of enzymatic activity, 
most likely due to the presence of the polar hydroxyl group. Additionally, p-nitro-5-
phenylthioribose exhibited no catalytic activity, despite the fact that a large number of 
phenyl-substituted ribose analogs have been identified as highly potent inhibitors of 
MTRK and organismal growth [27]. Accordingly, it seems that MTRK possesses a 
certain degree of promiscuity for substitutions at the 5’ position, with a high 
discrimination towards hydrophobic groups, and with group size potentially being of 
lesser importance towards binding. In addition, a computational model of the K. 
pneumoniae active site incorporating MTR into the binding pocket implicates a large 
degree of freedom regarding rotation of the 5-carbon groups. Though Leu345 in the B. 
subtilis crystallographic structure (Leu349 for Klebsiella MTRK) was proposed to act as a 
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hydrophobic component of the binding pocket, its carbonyl group presents itself towards 
the binding pocket at a distance of approximately 6Å from the sulfur component of MTR 
(Figure 2.6). This may help in recognition of MTR by the coordination of a water 
molecule between the enzyme and substrate and serve to explain why 5-deoxyribose was 
not able to be utilized as a substrate. 
Kinetic mechanism determination – In order to determine the substrate reaction 
order, product inhibition studies were performed with MTR-1P. The analogous assay 
with ADP could not be performed due to constraints of the linked enzymatic assay.  
 
 
Figure 2.6. Modeled binding site of K. pneumoniae MTRK. The region 
incorporating the 5-carbon region of MTR permits a high degree of freedom regarding 
group size and orientation. The carbonyl moiety of Leu349, may coordinate with the sulfur 
atom of the substrate. 
Double reciprocal plots of MTR-1P against both MTR and ATP substrates are 
presented in Figure 2.7. The results are consistent with an ordered sequential binding 
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order based on Cleland’s rules, where MTR-1P appears to be the first product released 
[43]. 
Due to constraints of the linked-enzymatic assay utilized, the substrate binding 
order could not be directly examined, however, we herein propose a binding order based 
on our data’s conformity to mechanistic indications derived from protein structure and 
homology. In X-ray crystallographic studies of B. subtilis MTRK [20], structures were 
solved exclusively with ATP derivatives and in its unbound form. No equivalent 
structures containing bound MTR could be obtained, suggesting ATP as the catalytic 
initiator. Additionally, structural analysis of MTRK identified the two most closely 
related proteins as being choline kinase and aminoglycoside phosphotransferase type IIIa 
[20]. Both have been identified as functioning via a sequential binding mechanism with 
ATP being the first substrate bound [1][32]. Structurally similar mammalian kinases such 
as casein kinase and cAMP-dependent protein kinase also exhibit a sequential ordered 
 
 
Figure 2.7. Double reciprocal plots of MTR-1P product inhibition. Left panel 
shows MTR-1P product inhibition against MTR substrate, ● = 0, ■ = 50, ▲ = 100, ▼ = 
200 µM MTR-1P. Right panel shows MTR-1P product inhibition against ATP substrate, 
● = 0, ■ = 20, ▲ = 50, ▼ = 100 µM MTR-1P. Both inhibition profiles are indicative of a 
mixed mode of inhibition. 
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mechanism with ATP binding first [29]. Examination of the enzyme binding site would 
corroborate this conclusion, as ATP appears to be placed in an occluded cleft within the 
binding pocket where the clearest route to the ATP-binding pocket is through the site of 
MTR binding (Figure 2.6). This would seem to necessitate an ordered sequential 
mechanism with the binding of ATP occurring prior to MTR. This organization of 
substrates would seem to necessitate a sequential binding mechanism in order to allow 
catalysis. 
Our product inhibition data is consistent with these alternate data and accordingly, 
we suggest an identical mechanism for MTRK, wherein ATP binds first, followed by 
MTR with MTR-1P and ADP products being released, in order (shown in Figure 2.8). 
ATP MTR MTR-1P ADP
E EA EAB EPQ EQ E  
Figure 2.8. Cleland line describing MTRK binding. A sequential binding order with 
ATP binding first and methylthioribose-1-phosphate as the first product released. 
Conclusion 
MTRK is essential component of the methionine salvage pathway in the 
pathogenic bacteria K. pneumoniae. The gene does not form an operon with other genes 
responsible for methionine recycling, and appears to be under the regulatory control of 
elements involved in both purine and methionine metabolism. The purified enzyme 
displayed a specific activity of 6.2 µmol/min/mg, and the substrates MTR and ATP had 
apparent Km values of 21 and 70 µM. Enzyme activity towards analogs of MTR revealed 
the enzyme to favor molecules with short, hydrophobic 5-carbon substitutions, and 
product inhibition studies implicate an ordered sequential reaction order. We expect this 
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data can be used to design inhibitors with characteristics to perform as more potent 
antibiotics against target organisms. 
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CHAPTER 3: PAPER #2 – DRUG INHIBITION of Klebsiella pneumoniae 5’-
METHYLTHIOADENOSINE/S-ADENOSYLHOMOCYSTEINE NUCLEOSIDASE 
Abstract 
5’-Methylthioadenosine/S-adenosylhomocysteine nucleosidase (MTN) is an 
enzyme responsible for catabolism of the three downstream products of S-
adenosylmethionine dependent reactions important for cellular fitness and proliferation. 
Here we present a kinetic examination of purified, recombinant MTN from the Gram-
negative pathogen Klebsiella pneumoniae. For the three MTN substrates of 5’-
methylthioadenosine, S-adenosylhomocysteine, and 5’-deoxyadenosine, we have 
established Km values of 5.8 ± 0.8, 4.7 ± 0.2 and 7.0 ± 0.4 µM, and specific activities of 
15.4, 5.9, and 11.3 µmol/min/mg, respectively. The enzyme inhibitory activities were 
determined for four previously described transition-state analogs and four novel non-
nucleoside small molecules inhibitors. Transition-state inhibitors consistently possessed 
inhibition constants in the high picomolar range, and the small molecule inhibitor Ki 
values were grouped in the low micromolar range. 
Introduction 
S-adenosylmethionine (SAM) is a molecule with a central role in a broad array of 
metabolic processes. Created by the addition of methionine to ATP, SAM is utilized in a 
multitude of disparate pathways in K. pneumoniae. Predominantly, SAM is utilized as the 
most common methyl group donor for the transmethylation of biomolecules such as 
DNA, tRNA, proteins, carbohydrates, lipids, etc. [5].  In addition, SAM is the precursor 
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for the synthesis of polyamines, the production of quorum-sensing autoinducer 
molecules, and a substrate for radical-SAM enzymes responsible for the synthesis of 
vitamins and cofactors such as pyrroquinoline quinone (Figure 3.1) [24][23]. The MTN 
enzyme serves to deadenylate the three unique products of SAM metabolism, 5’-
methylthioadenosine (MTA), S-adenosylhomocysteine (SAH), and 5’-deoxyadenosine 
(5’dADO). These three nucleosides all function as potent product inhibitors for their 
respective enzymes [5] and the buildup of MTA is known to be toxic at high 
physiological concentrations [20]. The products of MTN reactions, 5-methylthioribose 
(MTR) and S-ribosylhomocysteine (SRH), are recycled to methionine by subsequent 
enzyme reactions, while the fate 5-deoxyribose (5-dRIB) is still unknown. 
A role for MTN in microbial virulence has been proposed in Staphylococcus 
aureus where MTN gene knock-out strains failed to cause infectious mortality in mice 
[3]. MTN gene knock-outs in pathogenic E. coli O157:H7 also demonstrated reduced 
growth rates, cellular adhesion, biofilm formation, and Shiga toxin production [20]. 
These effects were reversible by vitamin supplementation, suggesting that loss of MTN 
led to 5’dADO accumulation and behavioral changes due to product inhibition of SAM-
dependent reactions involved in vitamin synthesis. 
As antibiotic resistance becomes increasingly widespread, the need for novel 
treatments becomes increasingly urgent. This is of particular concern regarding the 
bacterial species Klebsiella pneumoniae, which is notorious for the frequency and 
expansiveness of its antibiotic resistance profile. This organism is the most common 
among the carbapenem-resistant Enterobactericeae, and clinical isolates typically bear  
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Figure 3.1. Central role of MTN in catabolism of the products of SAM-dependent 
reactions. MTN catabolizes three distinct products of SAM metabolism. All three 
substrates are product inhibitors of their formative transmethylation, SAM-radical, and 
polyamine syntheses. 
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multiple resistances [6][27]. The conserved utilization of MTN in many pathogenic 
bacteria and numerous protozoan parasites and its absence in mammals provides an 
opportunity for the development of a novel broad spectrum antimicrobial agents [5].  
To date, investigations into inhibitors targeting MTN have yielded mixed results. 
Some bacterial species (H. pylori, B. burgdorferi) appear to be highly sensitive to MTN 
inhibitors [27][15]. Other organisms (E. coli, S. aureus, V. cholera) have their growth 
unaffected by inhibitors, but display reductions in autoinducer-2 secretion and biofilm 
formation [3][8][12]. Research on MTN inhibitors has largely focused on MTA analogs, 
and early and late-stage transition state analogs (TSAs) [28][12][13]. Both types of 
inhibitors exhibit strong binding towards E. coli MTN, with the late-stage transition state 
analogs in particular displaying among the tightest known non-covalent binding 
properties observed in biological systems, with some Ki values against E. coli MTN 
being placed in the low femtomolar range [12].  
The K. pneumoniae and E. coli MTN amino acid sequences show a greater than 
90% identity and complete conservation of catalytic residues (Figure 3.2). Despite this, 
previous reports have shown that the native K. pneumoniae MTN displayed a Km for the 
MTA substrate that was more than 20-fold greater than that of the E. coli enzyme 
E.coli            MKIGIIGAMEEEVTLLRDKIENRQTISLGGCEIYTGQLNGTEVALLKSGIGKVAAALGAT 60 
K.pneumoniae      MKIGIIGAMEEEVTLLRDKIENRQTITIGGSEIYTGQLHGVDVALLKSGIGKVAAAMGAT 60 
 
E.coli            LLLEHCKPDVIINTGSAGGLAPTLKVGDIVVSDEARYHDADVTAFGYEYGQLPGCPAGFK 120 
K.pneumoniae      LLLERCQPDVIINTGSAGGLASTLKVGDIVVSDEARYHDADVTAFGYEYGQLPGCPAGFK 120 
 
E.coli            ADDKLIAAAEACIAELNLNAVRGLIVSGDAFINGSVGLAKIRHNFPQAIAVEMEATAIAH 180 
K.pneumoniae      ADEKLVAAAESCIKALDLNAVRGLIVSGDAFINGSVGLAKIRHNFPQAIAVEMEATAIAH 180 
 
E.coli            VCHNFNVPFVVVRAISDVADQQSHLSFDEFLAVAAKQSSLMVESLVQKLAHG  232 
K.pneumoniae      VCHNFKVPFVVVRAISDVADQQSHLSFEEFLAVAARQSTLMVENLVQNLARG  232 
                 
Figure 3.2. ClustalOmega alignment of E. coli and K. pneumoniae MTN 
sequences. The two sequences show an identity greater than 90%, with residues 
critical for substrate binding and catalysis strictly conserved and highlighted [21]. 
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[17][22]. This apparent diversity of substrate recognition and catalysis poses a potential 
challenge for subsequent inhibitor development. In order to improve our understanding of 
the K. pneumonia MTN, we have cloned the MTN gene and characterized the specific 
activity and substrate kinetics of the recombinant enzyme. Finally, a series of MTN 
transition-state analogs and small molecule inhibitors were tested for enzyme inhibition 
to provide a framework for future drug design. 
Materials and Methods 
Chemicals and substrates: The transition state analogs MTD – (3R, 4S)-1-[(9-
deazaadenin-9-yl)methyl]-3-hydroxy-4-(methylthiomethyl)pyrrolidine; BTD – (3R,4S)-
4-(butylthiomethyl)-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxypyrrolidine; BCX – (1S)-
1-(9-deazaadenin-9-yl)-1,4-dideoxy-1,4-imino-5-methylthio-D-ribitol; BCZ - (1S)-1-(9-
deazaadenin-9-yl)-1,4-dideoxy-1,4-imino-5-propyl-D-ribitol were kindly provided by Dr. 
Vern Schramm (Albert Einstein Medical College, Bronx, NY). The non-nucleoside small 
molecule inhibitors 5A - (N-(2-furylmethyl)-N’-(4-nitrophenyl)urea); 8A - 1-(4-
nitrophenyl)-3-[4-[4[(4-nitrophenyl) carbamoylamimino] phenoxy]phenyl]-urea; 15A - 2-
[2-(5,6-dimethyl-1H-benzoimidazol-2-yl)vinyl]-5,6-dimethyl-1H-benzoimidazole; 27A - 
3-(1,3-benzothiazol-2-yl)-1-(5-{[(1,3-benzothiazol-2-yl)carbamoyl]amino}-2-
methylphenyl)urea were obtained from the National Cancer Institute Developmental 
Therapeutics Program. 
Identification of non-nucleoside inhibitors: The small molecule inhibitors tested 
here were identified based on the results of in silico screening of the NCI Diversity Set II 
small molecule library against the E. coli MTN structure performed by Dr. Danny Xu 
(Idaho State University, School of Pharmacy) and an enzyme analysis of the top thirty-
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three compounds (unpublished results). The four most potent inhibitors against E. coli 
MTN (designated 5A, 8A, 15A, and 27A) were selected for assessment against K. 
pneumoniae MTN. 
MTN plasmid creation and cell transformation: The MTN gene was amplified 
from Klebsiella pneumoniae (ATCC strain 43816) by whole-cell PCR using the primer 
pair KPMTNF (5’–ATGAAAATTGGCATTATTGGCG-3’) and KPMTNR (5’–
GCCACGTGCCAGGTTCTGTACC- 3’). The 696 base pair product was ligated into the 
C-terminal poly-His-encoding pTrcHis-TOPO plasmid (Invitrogen) according to 
manufacturer’s instructions before being transformed into chemically competent E. coli 
One Shot™ TOP10 cells (Invitrogen) and purified using the GeneJET Plasmid Miniprep 
Kit (ThermoFisher). The purified plasmid was transformed into chemically competent E. 
coli OneShot™ BL21 (DE3) cells (Invitrogen). The insertion orientation was confirmed 
by PCR using the KPMTNF primer and a pTrcHis-TOPO manufacturer-provided 
external reverse primer. The plasmid sequence with the gene insertion was confirmed by 
sequencing services provided by GeneWIZ, Inc. 
Protein expression and purification: Transformed BL21 cells were grown in 
500mL LB broth at 30°C to an OD600 of 0.5, and induced with 0.5mM IPTG overnight. 
Cells were harvested by centrifugation (5000 x g, 15 min), and the pellets were washed 
once with PBS. The washed cell pellet was homogenized in 3mL B-PER® 
(ThermoFisher) reagent for 15 minutes at room temperature. Cell debris was removed by 
centrifugation (10000 x g, 25 min). The recombinant Klebsiella MTN was purified from 
the clarified supernatant using 3mL cobalt HisPur™ resin (ThermoFisher) according to 
manufacturer’s instructions. Briefly, the recombinant enzyme was bound to the column 
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by an overnight incubation at 4ºC. Unbound material was removed by centrifugation at 
700 x g for two minutes. The column was washed three times with 3mL wash buffer 
(10mM imidazole, 50mM NaPO4, 300mM NaCl, pH= 7.4), and the recombinant protein 
eluted with three 1.5mL volumes of elution buffer (250mM imidazole, 50mM NaPO4, 
300mM NaCl, pH= 7.4). Protein quantity was assessed by Bio-Rad protein assay 
performed with a bovine serum albumin standard, and the purity was confirmed by SDS-
PAGE using PageRuler Plus Prestained Protein Standard (ThermoFisher) and stained 
with Coomassie Blue. The concentration of pure enzyme was adjusted to 70 µg/mL in 
20% glycerol, and stored at -80ºC before use in spectrophotometric enzyme assays. 
Enzyme activity and kinetics: Nucleosidase assays were performed as previously 
described [12]. Briefly, 1mL reactions contained 100mM sodium phosphate buffer (pH 
6.5), and 1-50 µM substrate (MTA, SAH, or 5’dADO) at 25°C. Reactions were initiated 
by the addition of 0.7 µg of enzyme. Reaction velocities were monitored at 275nm using 
a Varian Cary-50 spectrophotometer (Ԑ275 = 1.60 mM-1cm-1) and the data was fit to the 
Michaelis-Menten equation with GraphPad Prism 6.0 software: 
  ݒo ൌ ݒmaxሾܵሿ ሺܭm ൅ ሾܵሿሻ⁄       Eqn. 1 
Inhibition assays: For assessment of TSA inhibition, reaction conditions were 
performed as with kinetics assays. Transition-state analog inhibition was measured at 2-
500 nM in the presence of 50 µM MTA and fit to the modified equation for competitive 
inhibition as previously described [12].  
ݒo′ ݒo ൌ ሺܭm ൅ ሾܵሿሻ ሾሺܭm ൅ ሾܵሿሻ ൅ ሺܭmሾܫሿ ܭiሻሿ⁄⁄⁄    Eqn. 2 
For analysis of non-nucleoside small molecule inhibitors, concentrations of 0.1- 
10 µM were used. MTA substrate concentrations were varied between 5-50 µM. Data 
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was fit to the equations for competitive inhibition, noncompetitive inhibition, and mixed 
inhibition using GraphPad Prism 6.0 software. Data from all four small molecules (5A, 
8A, 15A, 27A) fit best to the competitive inhibition model. Subsequently, the small 
molecule inhibitors were tested as described for the transition state analogs and the data 
fit to the modified equation for competitive inhibition (Eqn. 2). 
Results and Discussion 
Enzyme purification – SDS-PAGE analysis of the purified, recombinant MTN 
(with C-terminal poly-His purification sequence) showed a >95% purity and an apparent 
molecular weight of 30 kD (Figure 3.3). This is in close agreement with the ProtParam 
[29] calculated molecular weight of 29.7 kD, based on the amino acid sequence and prior 
reports for the 26.5 kD native enzyme [17].  
 
Figure 3.3. SDS-PAGE gel of recombinant K. pneumoniae MTN. Lane 1: Protein 
molecular weight standard. Lane 2: 2µg recombinant MTN. The estimated molecular 
weight for purified rMTN is 30 kD. 
Substrate kinetics – All three substrates demonstrated typical Michaelis-Menten 
kinetics (Figure 3.4).  
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Figure 3.4. Substrate velocity plots. Data is shown for the substrates 5’-
methylthioadenosine (left), S-adenosylhomocysteine (middle), and 5’-deoxyadenosine 
(right). All data was fit to Michaelis-Menten equation using GraphPad Prism 6.0 
software. 
Enzyme activity and kinetic constants for each native substrate are summarized in 
Table 3.1. Specific activities for the three substrates (measured at 50 µM) ranged from 
5.3 to 13.8 µmol/min per mg of enzyme. MTA was the most efficiently catalyzed 
substrate, consistent with previous reports for numerous other bacterial enzymes 
[22][15][8][25]. The Km values for MTA and SAH (5.8 and 4.7 µM, respectively) are in 
good agreement with previously reported values of 8.1 µM and 4.3 µM for native K. 
pneumoniae MTN purified from cellular extracts [17]. The Km for 5’dADO was 7 µM. 
This is the first reported kinetic study for this substrate. MTN demonstrated the highest 
catalytic rate (460 min-1) and efficiency (79 µM-1min-1) for MTA. The catalytic 
efficiencies for SAH and 5’dADO substrates were approximately half the values obtained 
for MTA. 
Table 3.1. Summary of MTN Kinetic Constants 
 Specific Activity 
(µmol/min/mg) 
Km  
(µM) 
vmax 
(nmol/min) 
kcat  
(min-1) 
kcat/Km  
(µM-1min-1) 
MTA 13.8 5.8 ± 0.8 10.8 460 ± 20 79 
SAH 5.3 4.7 ± 0.2 4.1 174 ± 3 37 
5’dADO 9.8 7.0 ± 0.4 7.1 335 ± 7 48 
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The K. pneumoniae MTN substrate specific activities for MTA and SAH are 
approximately 30-fold lower than the corresponding specific activities reported for the E. 
coli enzyme (373 and 156 µmol/min per mg of enzyme, respectively) [22]. In addition, K. 
pneumoniae MTN displays a fourteen-fold increase in Km for MTA relative to the E. coli 
enzyme (5.8µM vs. 0.4 µM), while the Km for SAH is highly similar for the two enzymes 
(4.7µM to 4.3µM for E. coli) [22]. As K. pneumoniae possesses a complete enzyme 
pathway to recycle methionine from MTR while E. coli does not, the increased activity of 
the E. coli enzyme most likely represents an evolutionary adaptation in order to help 
maintain low intracellular concentrations of toxic MTA. 
Inhibition values – Four transition-state analogs and four competitive inhibitors 
identified by in silico screening were tested against K. pneumoniae MTN. Fits of the 
inhibition data to the equation for competitive inhibition are provided in Appendix A. As 
previously described, the TSA molecules all show discrete early and late-onset inhibition 
profiles resulting from a latent conformational transition of the enzyme-inhibitor complex  
[12]. Representative graphs for the late-transition state analog MT-DADMe ImmA 
(MTD) are shown in Figure 3.5. 
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Figure 3.5. Inhibition of MTN activity by MTD. A) Kinetic activity profiles B) 
Early-onset inhibition graph C) Late-onset inhibition graph. Data was fit to the modified 
equation for competitive inhibition (Eqn. 2) [12]. 
As expected, TSAs showed binding interactions with the enzyme that were 3-4 
orders of magnitude stronger than for than the non-nucleoside inhibitors (Figure 3.6).  
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Relative binding affinities of the inhibitors towards K. pneumoniae and E. coli 
enzymes reflected the observed discrepancies between MTA substrate activities. In 
general, the E. coli enzyme shows inhibition constants for the TSAs within the 
femtomolar to picomolar range in contrast to the inhibition constants for the Klebsiella 
MTN that are reported here. For the early stage (BCX, BCZ) and late stage (MTD, BTD) 
TSAs, the Ki values were 10-fold, and 125 to 675-fold higher, respectively, than the 
values determined against the E. coli enzyme [12]. Binding affinities of the four non-
nucleoside inhibitors were also lower than the 20-600 nM Ki values observed against E. 
coli MTN (unpublished data). 
Previously, Gutierrez, et al. compared the Ki values of BCX and MTD to classify 
MTN mediated catalysis according to early dissociative or late dissociative transition 
 
MTD BTD BCX BCZ 
Ki  = 1.00 ± 0.01 
nM 
Ki* = 0.25 ± 0.03 
nM 
Ki  = 1.3   ± 0.2 nM 
Ki* = 0.20 ± 0.03 nM 
Ki  = 4.2 ± 0.3 nM 
Ki* = 0.8 ± 0.1 nM 
Ki  = 1.2   ± 0.2 nM  
Ki* = 0.62 ± 0.08 
nM 
 
5A 8A 15A 27A 
Ki = 8.8 ± 0.5 µM Ki = 3.5 ± 0.4 µM Ki = 4.8 ± 0.4 µM Ki = 1.3 ± 0.2 µM 
Figure 3.6. Summary of inhibition constants. Late-stage transition-state analogs 
are represented by MTD and BTD, and early-stage by BCX and BCZ. The four novel 
small molecule inhibitors are shown in the second row. All transition-state analogs 
demonstrated discrete early and late-onset inhibition profiles with picomolar to 
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state models [19]. High fold increases (>40) in binding affinity for the late-stage TSA 
MTD relative to the early-stage TSA BCX indicated a late dissociated transition state. 
Interestingly, the disparity in K. pneumoniae MTN affinities between early-stage and 
late-stage TSAs were less dramatic than previously reported [19]. Our studies show only 
a 3.4-fold improved affinity for MTD relative to BCX. This is largely due to a lower 
observed Ki value for BCX (0.84 nM) compared to the 45nM reported in the initial study 
[19]. Our data suggests that the K. pneumoniae MTN adheres more closely to an early 
dissociative transition state model that is more similar to N. meningitides and H. pylori 
MTNs than to the more evolutionarily related E. coli enzyme. 
Conclusion 
Klebsiella pneumoniae MTN possesses a highly similar sequence identity to that 
of E. coli, but demonstrates a 14-fold higher Km value for MTA and a 30-fold reduction 
in specific activity relative to what is reported for the E. coli enzyme. Likewise, both 
transition-state analogs and non-nucleoside small molecule inhibitors were found to have 
lesser capacities for enzymatic inhibition. This highlights an unexpected degree of 
variability in activity among highly homologous enzymes, which could influence the 
direction of future drug design to exploit the differences between species. We also report 
the identification of a new set of non-nucleoside inhibitors of MTN, which will serve as a 
starting point for our goal to develop MTN inhibitors that will circumvent the 
inconsistent effects on cellular behavior observed for the otherwise potent transition state 
analog inhibitors. 
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CHAPTER 4: PAPER #3 – INFLUENCE OF MTA/SAH NUCLEOSIDASE ACTIVITY 
ON BACTERIAL GROWTH AND VIRULENCE FACTOR GENE EXPRESSION 
Abstract 
The enzyme 5’methylthioadenosine/S-adenosylhomocysteine nucleosidase 
(MTN) is widely utilized among bacterial species and is involved in a diverse set of 
metabolic pathways. Investigations of drugs targeting this enzyme have identified strong 
enzymatic inhibitors that have shown disproportionately weak effects when used as 
therapeutics against most bacterial organisms. We present here an examination of the 
effects of transition state analog and novel non-nucleoside MTN inhibitors against the 
pathogenic bacteria Klebsiella pneumoniae. These inhibitors showed pleiotropic effects 
on cell growth, with members of both inhibitors types capable of inducing either growth 
deficiencies or enhanced growth rates. Neither of the two classes of MTN inhibitors were 
able to cause significant alterations in biofilm formation. Lysates of cells treated with 
TSA inhibitors had no observed alterations in MTN activity, but appear to display an 
increase in intracellular MTN concentration. K. pneumoniae treated with a TSA inhibitor 
showed upregulation of two siderophore genes and downregulation of a matrix binding 
protein. A supplemental examination of gene expression in an MTN gene knock-out in 
enteropathogenic E. coli O157:H7 showed significantly decreased expression in both 
Shiga-like toxins, hemolysin, and a component of type 3 secretory system relative to the 
wildtype strain. The results of these studies suggest antibiotics targeting MTN are 
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capable of producing effects on cellular proliferation and the expression of different 
virulence-associated genes in Klebsiella. 
Introduction 
Klebsiella pneumoniae is Gram-negative bacterium best known for its role as a 
nosocomial pathogen. K. pneumoniae is currently recognized as one of the eight most 
severe hospital-associated infectious agents [1]. As a pathogen, K. pneumoniae is notable 
for the breadth of antibiotic resistance genes found in clinically isolated strains. K. 
pneumoniae is the most common Carbapenem-resistant Enterobactericeae (CRE), and 
was the origin for both Klebsiella pneumoniae carbapenemase (KPC) and New-Delhi 
metallo-β-lactamase resistance genes [2][3]. Infectious strains of this organism typically 
carry multiple extended-spectrum β-lactamases and carbapenemases, providing a 
significant challenge for effective treatment [4]. This combination of drug resistances has 
resulted in outbreaks with mortality rates that exceed 50% [5]. 
The 5’methylthioadenosine/S-adenosylhomocysteine nucleosidase (MTN) 
enzyme is responsible for the hydrolytic breakdown of three distinct products of SAM-
dependent metabolic pathways in many bacterial species. These substrates are: 5’-
methylthioadenosine (MTA), S-adenosylhomocysteine (SAH), and 5’deoxyadenosine 
(5’dADO). Apart from the degradation of the toxic molecules MTA and SAH [6], MTN 
is additionally involved in the production of multiple metabolites important for cellular 
fitness. Metabolic processes expected to be impacted by the disruption of MTN activity 
include: methylations, polyamine synthesis, autoinducer production, purine and 
methionine salvage, and the synthesis of vitamins used in central carbon metabolism [7]. 
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Transition state analog inhibitors of the MTN enzyme have displayed binding 
properties that are among the strongest non-covalent interactions observed in biological 
systems [8]. These inhibitors have shown potent bactericidal activity against the purine 
auxotrophs Helicobacter pylori and Borrelia burgdorferi [9][10]. However, applications 
of TSA inhibitors against E. coli and V. cholerae did not impact growth, and instead 
caused reductions in biofilms and autoinducer-2 production [11]. MTN gene knock-outs 
performed in Staphyloccocus aureus, Neisseria miningitidis, and Escherichia coli 
O157:H7 have implicated the enzyme to be involved more strongly with virulence-
associated behavior than with cellular growth and fitness [12][13][14]. 
Materials and Methods 
Strains and growth conditions – K. pneumoniae (ATCC strain 43816) was grown 
in minimal media [15] modified to substitute chloride salts for sulfates. Briefly, minimal 
media contains: 25 mM NH4Cl, 35mM glucose, 1.5 mM KCl, 0.4 mM MgCl, 0.045 mM 
NaCl, 0.025 mM FeCl, 0.025 µg/mL thiamine, 66.6 mM sodium phosphate, 5x10-7 M 
CaCl2, 5x10-8 M CoCl2, 10-7 M MnCl2, 5x10-7 M HBO3, 10-8 M ZnCl2, 10-8 M CuCO3, 
5x10-9 M (NH4)6Mo7O24, pH 7.4.  The media was supplemented with 100µM MTA as a 
sulfur source. E. coli O157:H7 strains (ATCC 43894) were grown in Davis minimal 
media supplemented with 0.4% glucose, and either 25 µg/mL chloramphenicol (for MTN 
knock-out) or 50 µg/mL ampicillin + 25 µg/mL chloramphenicol (MTN knock-in). 
Inhibitors - The transition state analogs MTD – (3R, 4S)-1-[(9-deazaadenin-9-
yl)methyl]-3-hydroxy-4-(methylthiomethyl)pyrrolidine; BCX – (1S)-1-(9-deazaadenin-9-
yl)-1,4-dideoxy-1,4-imino-5-methylthio-D-ribitol; BCZ - (1S)-1-(9-deazaadenin-9-yl)-
1,4-dideoxy-1,4-imino-5-propyl-D-ribitol were kindly provided by Dr. Vern Schramm 
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(Albert Einstein Medical College, Bronx, NY). The non-nucleoside small molecule 
inhibitors 5A - (N-(2-furylmethyl)-N’-(4-nitrophenyl)urea); 8A - 1-(4-nitrophenyl)-3-[4-
[4[(4-nitrophenyl) carbamoylamimino] phenoxy]phenyl]-urea; 15A - 2-[2-(5,6-dimethyl-
1H-benzoimidazol-2-yl)vinyl]-5,6-dimethyl-1H-benzoimidazole; 27A - 3-(1,3-
benzothiazol-2-yl) -1 -(5- {[(1,3-benzothiazol 2-yl) carbamoyl] amino}-2-
methylphenyl)urea were obtained from the National Cancer Institute Developmental 
Therapeutics Program. 
Growth assays – K. pneumoniae cells were grown overnight in MTA 
supplemented minimal media. Cells were then diluted 1:5000 into fresh minimal media 
and 20µL was used to inoculate 160µL of media in the wells of Thermo Scientific® 
polystyrene 96-well plates. A 20µL volume of dissolved drug (or solvent control) was 
added to each well to achieve 10µM total drug concentration. Solubility complications 
required the non-nucleoside drugs to be dissolved in DMSO, therefore the volume of 
drug used was limited to 1% of the total culture volume to minimize inherent toxic 
effects, and a corresponding DMSO control was performed. Growth was monitored by 
hourly OD600 readings using a BioTek SynergyHT multiwell plate reader. All trials were 
performed in triplicate using a minimum of three replicates per drug. 
Biofilm assays – Biofilms were grown in 96-well plates that were inoculated in an 
identical fashion to the cell growth assays. The cells were allowed to grow without 
shaking at 30ºC over 72 hours. The cells were aspirated, and the wells washed three times 
with PBS before being fixed in 250µL 1% paraformaldehyde in PBS for 1 hour at 4°C. 
The wells were then washed twice with water, and stained with 250µL 0.1% crystal 
violet for 15 minutes at room temperature. Excess dye was removed with four washes 
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with water and the biofilm-bound crystal violet was solubilized using 250µL of a 20:80 
mixture of acetone:ethanol for 10 minutes with gentle shaking. The absorbance of 
extracted crystal violet was measured at 595nm using a SynergyHT multiwell plate 
reader. 
Intracellular MTN activity – K. pneumoniae cells were grown overnight in 10mL 
sulfate-free minimal media supplemented with 100μM MTA and BCZ (MTN inhibitor) 
at concentrations of 0, 5, 10, 20 and 50μM. The cells were collected by centrifugation 
(10,000 x g, 15 min) and the cell pellets washed three times with PBS. Cells were lysed 
in 3mL B-PER® lysis reagent (ThermoFisher) over 15 minutes at room temperature with 
frequent vortexing. The cell debris was removed by centrifugation (10,000 x g, 25 min) 
and the clarified supernatants were collected. The supernatant protein concentration was 
estimated by absorbance at 280 nm (A0.1% = 1.0 mg/mL) and equivalent quantities of 
protein were assayed for MTN specific activity using a UV spectrophotometric assay as 
described by Singh, et al. [8]. 
Immunoblotting – Drug-treated cell lysates were electrophoresed on 15% SDS-
polyacrylamide gels. Replicate gels were stained using Coomassie Blue dye and imaged, 
or electroblotted onto PVDF membranes at 120V for two hours. For immunoblot analysis 
the membrane was blocked overnight with 1% nonfat dry milk in PBS + 0.1% Tween 20 
(PBST). The membrane was then washed three times with PBST and incubated for 30 
minutes with of mouse α-MTN antibody (1:500 dilution in 1% nonfat dry milk in PBST). 
The membrane was washed twice with PBST, and the primary antibody detected by 
incubation for 30 minutes with goat α-mouse HRP (1:1000 dilution in PBST). The 
membrane was washed three more times with PBST and chemiluminescence was 
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detected using 1mL SuperSignal™ ELISA Femto Substrate (ThermoFisher) with a 
FluorChem™ E imager (Protein Simple). 
Autoinducer Assays – K. pneumoniae cultures were grown in AB media [16] to 
early stationary phase (OD600 = 0.8) and the cells were harvested by centrifugation 
(10,000 x g, 20 min). The clarified supernatants were collected and filter sterilized using 
0.22 micron syringe filters. AI-2 dependent bioluminescence was measured using opaque 
96-well plates containing 180µL of a 1:5000 dilution of V. harveyi (BB 170) in AB 
media. Experiments were initiated by the addition of 20µL of Klebsiella culture 
supernatant and the plates were incubated at 30ºC. Luminescence readings were taken 
hourly using a BioTek SynergyHT multiwell plate reader over 24 hours. Relative 
bioluminescence was calculated at 12 hours post-inoculation as this time represented a 
maximal response for the positive control V. harveyi (BB120) strain supernatant, and 
luminescence values are presented as the ratio of luminescence to that of the BB120 
strain. 
qRT-PCR – Cellular RNA was extracted from either K. pneumoniae (ATCC 
43816) or E. coli (ATCC 43894) cells grown to late log phase in minimal media (OD600 = 
0.8) using the Qiagen RNEasy Miniprep Kit according to manufacturer’s instructions, 
with the inclusion of the optional DNase incubation step. Purified RNA was quantified 
using a NanoDrop™ (ThermoFisher). The sample RNA concentrations were equalized to 
100 ng/µL with RNase-free water. The primers used in the qRT-PCR assays are listed in 
Table 4.1 and Table 4.2. A 16S rRNA internal standard was used as a control. Primer 
amplification was confirmed against genomic DNA by visualization on 2% agarose gels 
stained with ethidium bromide. The qRT-PCR reactions were performed using a Verso 1-
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Step qRT-PCR ROX Kit (ThermoFisher), 0.1µg template RNA, 50 pmol forward and 
reverse primers, and amplified with a Lightcycler® 96 (Roche). The thermocycler 
program consisted of a 15 minute preincubation at 95ºC followed by 40 cycles of 95ºC 
(15 seconds) 55ºC (20 seconds) and 72ºC (50 seconds). The experiment was conducted 
twice with all reactions performed in triplicate. 
Table 4.1. Klebsiella pneumoniae virulence gene primers. 
Gene Protein Sequence 
Product 
size (bp) 
K2 Capsule component F: 5’-CAACCATGGTGGTCGATTAG -3’ 
R: 5’- TGGTAGCCATATCCCTTTGG -3’ 
531 
fimH-1 Type 1 pili F: 5’- ATGAACGCCTGGTCTTTTGC -3’ 
R: 5’- AGCTGAACGCCTATCCCCTG -3’ 
689 
mrkD Type 3 pili F: 5’- ACACCACCAACTATTCCCTC -3’ 
R: 5’- TGGAACCCACATCGACATTC -3’ 
243 
ycfM Fibronectin adhesin F: 5’- ATCAGCAGTCGGGTCAGC -3’ 
R: 5’- CTTCTCCAGCATTCAGCG -3’ 
160 
Kfu Iron channel F: 5’- GGCCTTTGTCCAGAGCTACG -3’ 
R: 5’- TCTGGCGCAGAGAATGCCAG -3’ 
632 
entB Siderophore F: 5’- ATTTCCTCAACTTCTGGGGC -3’ 
R: 5’- TATCGCGCATGAAAGCATCG -3’ 
384 
rmpA Capsule component F: 5’- GGTCTAAAGCAGTTAACTGGAC -3’ 
R: 5’- CCTTATGTACCCTTTACAGCC -3’ 
491 
Irp-2 Siderophore F: 5’- CTCAGGATTCGCTGTTACCGG -3’ 
R: 5’- TTCGGTCATGTTCGGCCAGG -3’ 
304 
ybtS Siderophore F: 5’- ACATCTGGCGTTACCAGAGG -3’ 
R: 5’- AGTGGTGCGTTCTGCGTCG -3’ 
469 
fyuA Iron channel F: 5’- ACATGATTAACCCCGCGACG -3’ 
R: 5’- AATGCCAGGTCAGGTCACTG -3’ 
547 
pfs MTN F: 5’- TCGTCGTCTCCGATGAAGCGC -3’ 
R: 5’- GCGACCGCAAGGAACTCCTC -3’ 
359 
16S 
rRNA 
Internal control F: 5’- TGGAGCATGTGGTTTAATTGGA -3’ 
R: 5’- TGCGGGACTTAACCCAACA -3’ 
159 
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Table 4.2. Escherichia coli virulence gene primers. 
Gene Protein Sequence 
Product 
size (bp) 
eaeA Intimin F: 5’- CGTCACCAGAGGAATCGGAG -3’ 
R: 5’- TCAGTCGCGATCTCTGAACG -3’ 
628 
Tir Intimin receptor F: 5’- TCAATGGCTTGCTGTTTGGC -3’ 
R: 5’- CAAAAGGCGTTGGGGAGTTG -3’ 
415 
Lpf1 Long-polar fimbriae F: 5’- GGTCAATAGTCGTTTCCGTA -3’ 
R: 5’- GGTCGTTGATTTAGGCAAAG -3’ 
410 
espB Type-3 secretion F: 5’- CCGATTGCCCCATACGATTC -3’ 
R: 5’- CTCTGGTCAAGGCTACGGAA -3’ 
474 
fimA Adhesin F: 5’- GTCCCTCAGTTCTACAGCGG -3’ 
R: 5’- CCGCATCAATCACCGTACCT -3’ 
269 
ppD Adhesin F: 5’- GCGTCATCAAAGCGGAAGAC -3’ 
R: 5’- GCACTCACCGACATGCTACA -3’ 
323 
Stx1 Shiga-like toxin 1 F: 5’- ACACTGGATGATCTCAGTGG -3’ 
R: 5’- CTGAATCCCCCTCCATTATG -3’ 
614 
Stx2 Shiga-like toxin 2 F: 5’- CCATGACAACGGACAGCAGTT -3’ 
R: 5’- CCTGTCAACTGAGCAGCACTTTG -3’ 
779 
hlyA Hemolysin A F: 5’- ACGATGTGGTTTATTCTGGA -3’ 
R: 5’- CTTCACGTGACCATACATAT -3’ 
165 
pfs MTN F: 5’- TGGGCGATATCGTTGTCTCG -3’ 
R: 5’- AGCCAGGAACTCATCGAAGC -3’ 
380 
16S 
rRNA 
Internal control F: 5’- TGGAGCATGTGGTTTAATTGGA -3’ 
R: 5’- TGCGGGACTTAACCCAACA -3’ 
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Results and Discussion 
Growth 
The effects of TSAs and small molecule non-nucleoside inhibitors (see Figure 3.6 
for structures) on Klebsiella pneumoniae growth were measured under multiple media 
conditions. Klebsiella pneumoniae growth in LB media and sulfate-containing minimal 
media was unaffected by TSA inhibitors at concentrations up to 20µM (data not shown). 
Similarly, the non-nucleoside inhibitors failed to impact growth in nutrient rich LB 
media. In order to improve the observed effects of inhibitor treatment, growth assays 
were performed in minimal media that contained the substrate MTA as the sole sulfur 
source. Among the transition state analog inhibitors, BCZ produced only moderate delays 
in reaching log-phase growth, with cultures reaching mid log-phase growth 
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approximately 4-5 hours after the untreated controls (Figure 4.1). BCX treatment 
accelerated growth relative to untreated cells, although the increased growth rate does not 
appear to be statistically significant. Potentially, the enhanced growth could be the result 
of transmethylthiolase activity that may degrade BCX and bolster the availability of  
 
 
Figure 4.1. TSA inhibitor effects on K. pneumoniae growth. K. pneumoniae 
cultures were incubated with 10µM of inhibitor in minimal media containing MTA as the 
sulfur source. The data shows the average of three independent experiments performed in 
triplicate (±SEM, n=9). 
sulfur. MTD treatment caused the most significant growth defects and delayed mid log-
phase growth by approximately 11 hours compared to the control. MTD is a more potent 
inhibitor of the MTN enzyme than BCX or BCZ (Figure 3.6), which likely accounts for 
its greater effect towards cellular growth. 
Among the non-nucleoside small molecule inhibitors, 8A and 15A treatments 
showed modest increases in cellular growth rates, while 5A treatment produced no 
observable effects (Figure 4.2). The inhibitor 27A successfully reduced the growth rate at 
mid-log and late-log phase growth, and resulted in an approximately 6 hour delay for the 
cultures to reach stationary phase. 
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Figure 4.2. Non-nucleoside inhibitor effects on K. pneumoniae growth. K. 
pneumoniae cultures were incubated with 10µM of inhibitor in minimal media containing 
MTA as the sulfur source. The data shows the average of three independent experiments 
performed in triplicate (±SEM, n=9). 
Biofilm Formation 
Treatment with TSA inhibitors failed to cause a statistically significant impact on 
biofilm formation (Figure 4.3). Despite having lesser effects on planktonic growth, BCX 
and BCZ appear to cause a decreased biofilm accumulation while MTD did not.  
 
Figure 4.3. TSA inhibitor effects on biofilm formation. K. pneumoniae cultures 
were incubated for 72 hours with 10µM inhibitor, and biofilm accumulation was 
measured using crystal violet staining. The results are the average of three independent 
experiments with drug treatments performed in triplicate (±SEM, n=9). 
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Similarly, the non-nucleoside small molecule inhibitors failed to significantly 
reduce the formation of biofilms in K. pneumoniae cell cultures (Figure 4.4). 
 
Figure 4.4. Non-nucleoside inhibitor effects on biofilm formation. K. pneumoniae 
cultures were incubated for 72 hours with 10µM inhibitor, and biofilm accumulation was 
measured using crystal violet staining. The results are the average of three independent 
experiments with drug treatments performed in triplicate (±SEM, n=9). 
The weak effect of MTN inhibitors on biofilm accumulation was not entirely 
unexpected. Although biofilms deposition has been found to be under partial control by 
autoinducer-mediated quorum sensing in certain bacteria [17][18], a luxS mutant of K. 
pneumoniae incapable of autoinducer-2 production showed defects only in the structure 
of microcolonies during the initial stages of biofilm development (less than 40 hours) 
[19]. 
Intracellular MTN 
Lysates of MTN inhibitor-treated K. pneumoniae did not exhibit differences in 
MTN specific activities relative to the untreated control (Table 4.3). Several factors could  
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Table 4.3. MTN activity in cell lysates following inhibition with BCZ 
 Untreated 5 µM 10 µM 20 µM 50 µM 
Specific Activity 
(nmol/min/mg) 5.464 5.594 5.465 5.306 5.516 
 
account for this observation. First, the inhibitors may not be efficiently transported into 
the bacterial cells. However, the inhibition of planktonic cell growth by MTD and BCZ 
(Figure 4.1) does not support poor drug uptake as the cause for a lack of effect on specific 
activity. Alternatively, the inhibitors may be degraded or the production of enzyme 
upregulated to achieve a homeostatic intracellular specific activity. Western blot analysis 
of cell lysates using an MTN-specific antibody suggest an apparent increase in 
intracellular MTN in response to drug treatment, although the response does not appear to 
be clearly dose dependent (Figure 4.5). This would suggest a regulatory mechanism to 
compensate for the deficiency of nucleosidase activity in cells following drug inhibition. 
Potentially, the inability to process MTA as a sulfur source would lead to a decrease in 
SAM concentrations that would alleviate MetJ repression and stimulate MTN expression. 
However, previous  research would suggest this is not the case, as no change in MTN 
specific activity under varied concentrations of exogenous methionine [20]. Indeed, an 
examination of the promoter sequence of the MTN gene reveals no strong matches for the 
consensus sequences associated with either methionine or purine regulatory elements 
(data not shown). However, MTN is also indirectly involved in the synthesis of many  
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Figure 4.5. Effect of inhibitor treatment on MTN expression. A) Coomassie 
stained SDS-PAGE of cell lysates. Lane 1: 0.1 μg recombinant MTN, Lane 2: PageRuler 
Plus Prestained Protein Ladder, Lane 3-7: lysates (25 µg protein/lane) from cells grown 
minimal media with 0, 5, 10, 20, and 50 μM BCZ (a, b, c, d, e). B) Immunoblot of a 
replicate gel using an MTN-specific antibody. 
additional metabolites and a further investigation into the regulatory mechanisms 
controlling the expression of MTN may elucidate the apparent genetic upregulation we 
have observed. 
Autoinducer-2 Production 
Treatment of Klebsiella cultures with the TSA inhibitor BCZ was predicted to 
result in MTN inhibition that would cause a decrease in Autoinducer-2 (AI-2) production, 
as has been shown in E. coli following treatment with TSAs [11]. AI-2 is typically 
assessed using a bioluminescent reporter strain of Vibrio harveyi that produces light in 
response to autoinducer detection. Unexpectedly, the BCZ-treated K. pneumoniae cell 
culture supernatants produced an enhanced V. harveyi bioluminescence response (Figure 
4.6). A significant induction of AI-2 dependent bioluminescence was observed when 
5µM or 10µM BCZ-treated culture supernatants were examined in the assay (relative to 
untreated control supernatants). The reason for this response is unclear. Potentially, this 
could be a result of the observed upregulation of MTN in treated cells that would 
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ultimately support a greater production of AI-2. Alternatively, it is possible that inhibitor-
induced changes in K. pneumoniae metabolism, capsule formation, cellular growth, or 
secreted virulence factors resulted in alterations in unexamined molecules also being 
presented to V. harveyi.  A reduction of harmful components in K. pneumoniae 
supernatants may have resulted in conditions that served to better facilitate the growth of 
V. harveyi and thereby further exaggerate the luminescence response. 
 
Figure 4.6. Bioluminescence assays. Average relative bioluminescence response, ± 
SEM, of V. harveyi BB170 scaled to values of V. harveyi BB120 supernatant positive 
control. * denotes p <0.05 by student’s T-test against untreated group, n=4. 
Gene Expression 
Since drug treatment produced effects on cellular behavior, we examined the 
potential effects of MTN inhibitor treatment on the transcriptional expression of genes 
involved in virulence for K. pneumoniae. The genes examined included those involved in 
mucoviscosity (K2, rmpA), cellular adhesion (fimH, mrkD, ycfM), siderophores (kfu, 
entB, irp2, ybtS, fyuA) and MTN. Transcription of most K. pneumoniae virulence genes 
were not strongly impacted by treatment with BCZ (Figure 4.7), though two genes related 
*
*
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to iron-scavenging (entB and irp2) showed a significant upregulation in transcript levels 
(1.2-fold and 3.4-fold increase, respectively). These genes are involved in the synthetic 
pathways for the siderophores enterobactin (entB) and yersiniabactin (irp2). This most 
probably represent a means of response to an exacerbated degree of metabolic starvation 
in minimal media that the previous growth assays indicate BCZ can induce. A reduction 
in transcriptional expression of the fibronectin-binding element ycfM was also observed, 
 
 
Figure 4.7. BCZ-induced alterations in K. pneumoniae gene expression. Average 
virulence factor expression (± SEM) represented as the change in threshold cycle relative 
to untreated cells (-∆Cq). * denotes p <0.1, and ** denotes p <0.05 by 1way ANOVA, 
n=6. 
though with less confidence than for entB or irp2. Data for K2 and MTN were omitted, 
since their transcript levels in treated and untreated cells were not significantly greater 
than the negative controls. This is possibly a result of the downregulation of MTN 
expression that occurs following mid-log phase [21], as the transcriptomes were 
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harvested from cells during early-stationary growth. Since western-blot evidence suggests 
that MTN protein expression is upregulated in drug-treated cells (Figure 4.5), we expect 
the transcript levels for MTN would corroborate this observation, but the transcript levels 
appear to be too low to be detected by this assay. It will be necessary to assess the 
comparative gene expression from cells harvested at an earlier phase of growth in order 
to better determine whether a change in MTN transcription has truly occurred. 
In order to assess a stronger direct causal relationship between MTN activity and 
the expression of virulence factors, three E. coli O157:H7 strains representing wildtype 
(WT), MTN knock-out (KO) and MTN knock-in (KI) were also compared for the 
expression of genes contributing to adhesion (lpf, eaeA, tir, ppD, fimA, espB), and for 
secreted virulence factors (stx1, stx2, hlyA). Statistically significant variations in gene 
expression were observed for both Shiga-like toxins (stx1, stx2), hemolysin (hly), and the 
type-3 secretory system component, espB (Figure 4.7). Shiga-like 1 was 3.6-fold 
decreased, and Shiga-like 2 was 2.2-fold decreased in the KO strain relative to WT. The 
other secreted virulence factor, hemolysin, also displayed a 2.8-fold transcript reduction 
from the WT, though with a lesser degree of confidence. Expression of espB was 2.4-fold 
decreased in the KO strain. The espB protein is a vital member of the secretory structure 
that enables cellular adhesion to mammalian cells. It functions by inserting the intimin 
receptor (tir) into the cell membranes of target cells to allow bacterial effacement through 
the intimin protein (eaeA) [22]. Through the expression of intimin and its receptor were 
not affected in the KO strain relative to WT, the reduction in espB transcription would act 
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Figure 4.8. Comparative gene expression in E. coli O157:H7 WT, MTN KO and 
MTN KI strains. Average virulence factor expression (± SEM) represented as the 
change in threshold cycle relative to untreated cells (-∆Cq). * denotes p <0.1, and ** 
denotes p <0.05 by 1way ANOVA, n=6. 
to subvert the activity of the binding mechanism as a whole. The observed decrease in 
transcriptional expression of these four genes serves to independently support the 
reported deficiencies in mammalian cell binding, hemolysin activity, and Shiga-toxin 
dependent Vero-cell cytotoxicity in the E. coli MTN KO strain [23]. Interestingly, the 
overexpression of MTN in the KI strain appears to have caused a significant change in 
the expression of Shiga-like toxin 1, and was increased 1.7-fold over the WT strain. This 
would suggest that Shiga-like 1 but not Shiga-like 2 is under positive regulatory control 
of MTN-dependent metabolism. This confirms the hypothesis that MTN activity plays an 
important role in supporting virulence phenotypes in E. coli and is therefore a valuable 
target in the search for a class of non-lethal antimicrobial agents that function by 
attenuating virulence.  
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Conclusion 
This work serves as a partial assessment of the potency of MTN inhibitors against 
Klebsiella pneumoniae growth and virulence. Cultures in modified minimal media were 
susceptible to drug treatments and showed changes in proliferation without affecting 
biofilm formation. Treatment with TSA inhibitors caused an apparent accumulation of 
MTN in cell lysates while maintaining equal enzyme specific activities. In addition, 
supernatants from cells treated with TSA inhibitors showed an increase in AI-2 
dependent luminescence response compared to untreated cells, though the reason for this 
is not yet understood. Drug treatments resulted in a transcriptional upregulation of two 
siderophore genes and a downregulation of an adhesion protein in K. pneumoniae. As a 
point of reference, E. coli O157:H7 MTN WT, KO and KI strains were also assessed for 
the expression of virulence genes. Relative to WT, the KO strain showed significant 
reductions in transcript levels for both Shiga-like toxins, hemolysin, and a secretory 
protein that contributes to cell adhesion. MTN inhibitors have largely shown poor results 
when used as antimicrobials, but our research demonstrates their potential application as 
drugs that act primarily through the debilitation of virulence and not through direct 
bactericidal activity. 
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CHAPTER 5: CONCLUSION 
The emergence and continual escalation of antibiotic resistances among 
pathogenic bacteria poses a danger to human health that must be addressed. The two 
bacterial enzymes MTN and MTRK provide unique opportunities for the development of 
unexploited classes of chemotherapeutic agents against a diverse array of infectious 
pathogens, including the important nosocomial agent Klebsiella pneumoniae.  
The variety of 5-alkylthio substituted substrate analogs that were found to be 
recognized by MTRK has enabled the identification of drugs that either selectively inhibit 
the methionine salvage pathway or are processed into toxic intermediates (Gianotti, et al., 
1990; Tower, et al., 1991). Substrate binding and product release of the enzyme were 
found to be consistent with an ordered sequential mechanism, with ATP binding first and 
MTR-1P released first. An analysis of MTR analogs showed that in general, compounds 
with bulky and polar 5-alkylthio substitutions were poorer substrates compared to shorter, 
hydrophobic substitutions. It is also likely that the sulfur atom plays a role in substrate 
acceptance, as 5’dRIB was not able to be utilized as a substrate. 
MTN represents a broad-functioning enzyme that has been heavily explored as a 
therapeutic target. However, the well characterized transition-state analog inhibitors of 
MTN have shown highly inconsistent effects on cellular behavior and cytotoxicity. A 
comparison between TSA inhibitors and an assortment of novel inhibitors derived from 
in silico screening against bacterial MTN established weaker binding affinities of the 
newly identified inhibitors compared to the transition-state analogs.  All of the inhibitors 
86 
 
examined showed lesser binding affinities towards K. pneumoniae MTN than against the 
E. coli enzyme. The impact of MTN inhibitors on Klebsiella cell growth was only 
measurable when the organism was cultured in minimal media that required MTN 
activity to salvage sulfur. Of the four small molecule MTN inhibitors only inhibitor 27A 
was potent enough to cause a decrease proliferation, which was most apparent during 
mid-log and late-log phase growth. None of the small molecule inhibitors caused 
significant effects on biofilm formation. Similarly, TSA inhibitors had variable impacts 
towards cellular growth, biofilms, autoinducer secretion, and the transcriptional 
regulation of important virulence factors. BCZ and MTD caused growth defects, but no 
discernable deficiency in biofilms. Treatment with BCZ also resulted in what appeared to 
be an increase in autoinducer-2 production and an upregulation in the transcription of two 
siderophore genes. K. pneumoniae appears to evade strong effects from MTN inhibitors 
by compensatory expression of MTN to combat enzymatic inactivation and by 
upregulation of iron-scavenging molecules that may ameliorate metabolic starvation. 
Although the MTN inhibitors showed strong inhibitory power against the enzyme, 
more work must be done to improve their ability to exert antimicrobial effects towards 
pathogens like K. pneumoniae. Using the structures of the four novel non-nucleoside 
small molecule inhibitors characterized here as a jumping-off point, work is already 
being undertaken to make structural modifications to improve their inhibitory strengths.  
We hope that this research presented here will serve to benefit the ongoing efforts 
to develop both MTRK and MTN inhibitors as a novel antibiotic agents. 
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APPENDIX 
MTN Inhibitor Fits to the Equation for Competitive Inhibition 
The section contains the complete set of data pertaining to the MTN inhibitors 
examined in Chapter 3. The four transition state analog inhibitors (MTD, BTD, BCX, 
BCZ) have two discrete inhibition values. The unmarked Ki values for the TSAs 
represent activity derived from initial enzyme velocities. Ki values labelled with “*” 
represent activities following delayed-onset increases in the binding affinity of the 
enzyme-substrate complex. The four examined non-nucleoside small molecule inhibitors 
(5A, 8A, 15A, 27A) displayed no delayed-onset inhibitory activity and possess a single 
Ki value. Velocities were related as a proportion of the untreated activity using a 
modified form of the Michaelis-Menten equation for competitive inhibition, where: 
ݒo′ ݒo ൌ ሺܭm ൅ ሾܵሿሻ ሾሺܭm ൅ ሾܵሿሻ ൅ ሺܭmሾܫሿ ܭiሻሿ⁄⁄⁄  
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